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Regulation of Runx2 Accumulation and Its Consequences 
Junko Shimazu 
Osteoblasts are bone-forming cells and therefore they are responsible of the synthesis of 
type I collagen, the main component of bone matrix. However, there is an apparent disconnect 
between the regulation of osteoblast differentiation and bone formation since the synthesis of Type I 
collagen precedes the expression of Runx2, the earliest determinant of osteoblast differentiation. 
Recently, genetic experiments in the mouse have revealed the existence of an unexpected 
cross-regulation between bone and other organs. In particular this body of work has highlighted the 
importance of osteoblasts as endocrine cells to regulate whole-body glucose homeostasis by secretion 
of a hormone, osteocalcin. However, the fundamental question of why bone regulates glucose 
homeostasis remained to be answered. Therefore, in my thesis, considering that bone is a 
metabolically demanding organ that constantly renews itself, I hypothesized that characterizing the 
connection between the need of glucose as a main nutrient in osteoblasts and bone development will 
provide a key to deeper understanding of why bone regulates glucose homeostasis.  
My work shows here that glucose uptake through GLUT1 in osteoblasts is needed for 
osteoblast differentiation by suppressing the AMPK-dependent activation by phosphorylation at S148 
of Smurf1 that targets Runx2 for degradation. I also uncovered the mechanism of action of Smurf1 in 
this setting. In a distinct but synergetic way, glucose uptake promotes bone formation by inhibiting a 
distinct function of AMPK. In turn, Runx2 favors Glut1 expression, and this feedforward regulation 
between Runx2 and Glut1 determines the onset of osteoblast differentiation during development and 
the extent of bone formation throughout life.  
Furthermore, I also identified that Smurf1 not only regulates osteoblast differentiation by 
targeting Runx2 for degradation but also contributes to whole-body glucose homeostasis by regulating 
the activation of osteocalcin by targeting the insulin receptor for degradation in vivo. These results 
identify Smurf1 as a determinant of osteoblast differentiation during development, of bone formation 
and glucose homeostasis post-natally. Most importantly, we show that these Smurf1 functions required 
AMPK-phosphorylation site S148 in vivo. 
Altogether, these results revealed the absolute necessity of glucose as a regulator of Runx2 
accumulation during osteoblast differentiation and bone formation in vivo and highlight the fundamental 
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1. The Basic Principles of Skeletal Cell Biology and Development 
The skeleton is one of the latest organs to appear during evolution and this makes vertebrates 
distinct and unique from other organisms. A key feature of the skeletal biology is that it is composed of 
two distinctive tissues, bone and cartilage, and contains three specific cell types: osteoblasts and 
osteoclasts in the bone and chondrocytes in the cartilage. The osteoblasts and chondrocytes originate 
from mesenchymal cell (Ducy et al., 1997) whereas osteoclasts are multinucleated cells that derive 
from hematopoietic progenitors in the bone marrow (Bar-Shavit, 2007). Each of these three cell types 
is responsible for unique functions that are important for the development as well as maintenance of 
the integrity of the skeleton. The earliest step of the skeletal development is the formation of the 
mesenchymal condensations at the location of the future skeletal elements. Subsequently, there are 
two developmentally distinct modes of skeletal development: intramembranous ossification and 
endochondral ossification. Intramembranous ossification, seen in only a few bones, allows 
mesenchymal condensations to differentiate directly into osteoblasts without any cartilaginous 
intermediate steps. In contrast, most skeletal elements are generated through endochondral bone 
formation that includes a cartilage intermediate stage (Karsenty and Wagner, 2002). Here, the two 
modes of skeletal development as well as the transcriptional regulation of differentiation and features 
of the functions of three specific cell types in the skeleton are described.  
 
i. Intramembranous ossification 
Intramembranous ossification is the characteristic process of ossification in parts of the skull and 
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the lateral halves of the clavicles (Yang and Karsenty, 2002). In addition, sutures, the junction between 
calvarial bones that are responsible for the maintenance of a separation between membranous bones 
and for regulating the expansive growth of the skull, are the major sites of intramembranous bone 
(Ornitz and Marie, 2002). The first step of the intramembranous ossification begins with the 
condensation of neural crest-derived mesenchymal cells at the location of future skeletal elements. 
During intramembranous ossification, the cells of the mesenchymal condensations differentiate directly 
into osteoblasts without intermediate processes (Figure 1) (Karsenty and Wagner, 2002). 
 
ii. Structural and functional features of osteoblast 
Osteoblasts are bone forming cells. They are responsible for the synthesis of a unique 
combination of bone extracellular matrix (ECM) proteins and they control the subsequent 
mineralization of the bone ECM (Ducy et al., 1997; Long, 2012). Histochemical and cytological 
analysis has shown that, during osteoblast differentiation, there is overall cell enlargement due to the 
increase in the size of the Golgi element, the accumulation of mitochondria as well as cytoplasmic 
basophilic materials (Pritchard, 1952). These observations are consistent with the notion that 
differentiated osteoblasts are metabolically active and engaged in the synthesis and secretion of 
collagenous and non-collagenous bone ECM proteins including osteocalcin, alkaline phosphatase and 
a large amount of type I collagen (Long, 2012). The metabolically active nature of osteoblasts is further 
supported by early studies demonstrating that a significant amount of glucose is consumed and used 
as a main nutrient by osteoblasts (Borle et al., 1960; Cohn and Forscher, 1962; Esen and Long, 2014). 
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Yet, despite its metabolically demanding nature, there is limited genetic and molecular studies 
addressing the fundamental importance of glucose uptake as a main energy source for osteoblast to 
fulfill its function during development and in postnatal life.  
 
iii. Bone extracellular matrix (ECM) and osteoblasts  
The bone extracellular matrix (ECM) contains two types of proteins, collagens and 
non-collagenous proteins that are mainly secreted by differentiated osteoblasts. The collagens in bone 
ECM is mainly type I collagen, a heterotrimeric protein made of two α1(I) chains and one α2(I) chain, 
which are encoded by two different genes (Vuorio and de Crombrugghe, 1990). Since Type I collagen 
secreted by differentiated osteoblasts, is by far the most abundant protein in the bone ECM, it is often 
used as a marker for bone formation by osteoblasts. The non-collagenous proteins, such as 
osteocalcin and alkaline phosphatase that are secreted by osteoblasts, compose 10 to 15% of total 
bone protein (Clarke, 2008). Approximately 25% of non-collagenous protein is exogenously derived, 
including serum albumin (Clarke, 2008). The synthesis of bone matrix starts from the deposition of 
organic matrix rich in type I collagen which is not yet mineralized (Florencio-Silva et al., 2015). 
Subsequently, mineralization occurs through the accumulation of calcium phosphate in the form of 
hydroxyapatite crystals, a major mineral crystal present in bone ECM, both within and between 
collagen fibrils (Florencio-Silva et al., 2015; Long, 2012). Bone mineral provides mechanical rigidity 
and load-bearing strength to bones, whereas the organic matrix provides elasticity and flexibility 
(Clarke, 2008).  
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iv. Transcriptional control of osteoblast differentiation  
 The earliest and most specific determinant of osteoblast differentiation is Runx2, a transcription 
factor that belongs to the runt-domain gene family, and is a vertebrate homolog of the Drosophila Runt 
protein (Ducy et al., 1997; Komori et al., 1997a). Runx2 is expressed in the cells of osteoblastic lineage 
and regulates osteoblast-specific expression of downstream target genes, such as Osteocalcin (Ocn), 
Osterix and Bone sialoprotein (Bsp) (Ducy et al., 1997; Nishio et al., 2006). Genetic studies have 
shown that Runx2 inactivation results in a complete absence of osteoblast differentiation (Figure 2) 
and its haplo-insufficiency, in mice and humans, results in cleidocranial dysplasia (CCD) (Komori et al., 
1997a; Lee et al., 1997a; Mundlos et al., 1997a; Otto et al., 1997d) (Figure 3). CCD that is caused by 
delay of osteoblast differentiation in bone forming through intramembranous ossification, is 
characterized by open fontanelles and short clavicles (Lee et al., 1997a; Mundlos et al., 1997a; Otto et 
al., 1997d). Conversely, an increase in Runx2 activity, as seen in mice and humans lacking one allele 
of Twist, results in craniosynostosis, characterized by early closure of the sutures, due to a premature 
osteoblast differentiation in the skull (Bialek et al., 2004) (Figure 4).  
Given the absolute necessity of Runx2 in osteoblast differentiation, the genetic regulation of 
osteoblast differentiation by Runx2 during development has been intensively studied. However, 
several aspects of Runx2 biology described below are still poorly defined.  
 
a. Contribution of Runx2 to bone formation 
It is assumed that Runx2 activity is required for the bone formation by differentiated osteoblasts 
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because in vitro Runx2 binds to and upregulates the activity of the promoter of α1(I) collagen, the main 
constituent of bone ECM and thus a marker for bone formation (Ducy et al., 1999; Kern et al., 2001). 
However, in vivo, type I collagen synthesis precedes Runx2 expression in prospective osteoblasts. 
Indeed, in mouse, the expression of α1(I) collagen is already observed in the mesenchymal 
condensation at E10.5 whereas Runx2 expression is not detectable in the cells of mesenchymal 
condensation before E12.5 (this study) (Figure 5). Therefore both, the contribution of Runx2 to bone 
formation and the molecular mechanism regulating Type1 collagen synthesis in vivo remain poorly 
understood. If Runx2 does not regulate the expression of α1(I) collagen in vivo, there is an apparent 
disconnect between differentiation and bone formation by osteoblasts. In other words, how bone 
formation is initiated once osteoblast differentiation has occurred remains largely unknown.  
 
b. Regulation of Runx2 accumulation by ubiquitination 
Another aspect of Runx2 biology that raises several important questions is understanding how its 
accumulation in osteoblast lineage cells during development is regulated. Since osteoblast 
differentiation is mainly controlled by Runx2, understanding how Runx2 accumulation is regulated in 
prospective osteoblasts during development will not only lead to a deeper understanding of the 
regulation of osteoblast differentiation but also will better delineate the pathological principles of bone 
diseases that are caused by improper osteoblast differentiation during development, such as CCD and 
craniosynostosis. For instance, a significant number of CCD patients do not have any detectable 
mutations in Runx2 (Puppin et al., 2005; Tessa et al., 2003), thus there might be other mechanisms 
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that once disrupted causes a delay of osteoblast differentiation and causes CCD.  
Recently, it has become apparent that the ubiquitination-proteasome system is involved in the 
regulation of bone turnover and Runx2 has been shown to be degraded through the 
ubiquitin-proteasome pathway (Severe et al., 2013; Tintut et al., 1999). Ubiquitin is a cellular signal that 
labels proteins as a post-translational modification to direct proteins to proteasome degradation (Dikic 
et al., 2009). The ubiquitination cascade involves the successive actions of three types of enzymes: E1 
ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme and E3 ubiquitin ligase. The E1 
ubiquitin-activating enzyme is responsible for recruiting ubiquitin. The E2 ubiquitin-conjugating enzyme 
transfers the ubiquitin to the targeted protein. The E3 ubiquitin ligase carries out the final step in the 
ubiquitination cascade and is acting as a scaffold protein that interacts with the E2 enzyme and 
transfers ubiquitin to the target protein (Dikic et al., 2009; Severe et al., 2013) (Figure 6). There are two 
major types of E3 ubiquitin ligase in eukaryotes, defined by the presence of either a HECT or a RING 
domain (Deshaies and Joazeiro, 2009). The important feature of the E3 ubiquitin ligases is that they  
confer substrate recognition, thus substrate specificity (Ardley and Robinson, 2005).  
Several E3 ubiquitin ligases have been implicated as regulators of bone formation postnatally 
(Jones et al., 2006; Shu et al., 2013; Yamashita et al., 2005; Zhao et al., 2004). Particularly, Smurf1, 
the HECT domain family of E3 ubiquitin ligase, is reported to regulate osteoblast differentiation by 
favoring the degradation of Runx2 in vitro (Zhao et al., 2003). Furthermore, a loss-of-function study 
showed that Smurf1-/- mice exhibited age-dependent increase in bone mineral density by promoting 
8 
 
degradation of the mitogen-activated protein (MAP) kinase, MEKK2, in vivo (Yamashita et al., 2005). 
Conversely, Smurf1 transgenic mice exhibited significantly reduced bone formation during postnatal 
life (Zhao et al., 2004). However, despite the biochemical evidence showing that Smurf1 targets Runx2, 
no genetic studies have yet addressed the role of Smurf1 as a regulator of osteoblast differentiation by 
targeting Runx2. 
Furthermore, given its involvement in skeletal development, there is a growing interest to better 
elucidate the mechanisms regulating Smurf1 activation. Smurf1, which is C2-WW-HECT E3 ubiquitin 
ligase, contains a catalytic HECT domain in the C-terminal, two WW domains (WW1 and WW2) and a 
phospholipid-binding C2 domain in the N-terminal region (Cao and Zhang, 2013) (Figure 7). The HECT 
domain interacts with both E2 and ubiquitin molecules during ubiquitination and the C2 domain binds 
to phospholipid-containing membranes and alters both subcellular localization and function of Smurf1 
(Cao and Zhang, 2013). The WW domains play a role to capture substrates which contain the PY motif 
(Cao and Zhang, 2013). In recent years, it has become apparent that a critical regulatory step for 
protein ubiquitination is phosphorylation of either substrate proteins or E3 ubiquitin ligases (Gallagher 
et al., 2006; Hayami et al., 2005; Xing et al., 2010). Indeed, several C2-WW-HECT E3 ligases are 
regulated by phosphorylation and their E3 ligase activity is enhanced by phosphorylation-induced 
confirmation changes (Gao et al., 2004; Xing et al., 2010). However, whether phosphorylation of 
Smurf1 is required for its activation to target Runx2 and/or other Smurf1 targets remain unknown. 
Although phosphorylation of Runx2 affects its degradation, Smurf1 is not involved in this 
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phosphorylation-dependent degradation of Runx2 (Shen et al., 2006; Xing et al., 2010). If Smurf1 
activation does depend on its phosphorylation, the important questions remained to be answered in 
vivo are: which kinase(s) phosphorylate(s) Smurf1 and which domain(s) if not amino acid(s) in Smurf1 
is/are needed to allow degradation of Runx2 degradation by favoring their phosphorylation.  
Altogether, rigorous genetic and molecular studies showing the mechanisms whereby regulation of 
osteoblast differentiation is regulated by E3 ubiquitin ligase will better delineate the molecular 
mechanism leading to Runx2 accumulation in osteoblast lineage cells during development. 
 
v. Endochondral ossification and chondrocyte differentiation 
The majority of bones develop through endochondral ossification, a two-step process involving 
chondrogenesis and osteognenesis. The first step of the endochondral bone development begins with 
the condensation of mesenchymal cells at the location of future skeletal elements, a prerequisite for 
subsequent chondrogenic differentiation (Karsenty and Wagner, 2002). In mouse, the formation of the 
mesenchymal condensation is observed after embryonic day E9.5. Subsequently, at E11.5, the 
expression of α1(I) collagen observed in the mesenchymal condensation is suppressed in 
mesenchymal cells that are differentiated into chondrocytes, the first skeleton specific cell type to 
appear during endochondral development (Dessau et al., 1980; Yang and Karsenty, 2002). The 
transcription factor Sox9 is a master regulator of the differentiation of mesenchymal cells into 
chondrocytes (Lefebvre and de Crombrugghe, 1998). The resulting chondrocytes have a characteristic 
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round-shape and rapidly proliferate and secrete a number of proteins for the cartilage extracellular 
matrix (ECM) that results in linear enlargement of the skeletal elements (Kronenberg, 2003). 
Particularly, Sox9 binds to and activates enhancer elements of aggrecan and α1(II) collagen that are 
considered as biological markers of the differentiating chondrocytes (Karsenty and Wagner, 2002; 
Lefebvre et al., 1997; Sekiya et al., 2000). In the cartilage ECM, the large aggregates of 
hyaluronan-aggrecan allow the tissue to withstand compression and type II collagen fibrils provide the 
framework for the tissue (Mackie et al., 2011). The undifferentiated mesenchymal cells that continue to 
express α1 (I) collagen remain at the periphery of the skeletal element and form the structure called 
perichondrium (Figure 8).  
Around E13.5, the innermost chondrocytes stop proliferating and become hypertrophic. These 
cells are called hypertrophic chondrocytes and no longer express α1(II) collagen, instead they express 
α1(X) collagen, the main specific marker for hypertrophic chondrocytes. Once chondrocyte 
hypertrophy is initiated, cells in perichondrium start to differentiate into osteoblasts to form a 
mineralized bony outer cortex structure around the cartilaginous core (Karsenty and Wagner, 2002; 
Maes et al., 2010). Eventually, hypertrophy chondrocytes die by apoptosis, allowing vascular invasion 
from the mineralized bone cortex (Mackie et al., 2008). The cartilage ECM surrounding hypertrophy 
chondrocytes is degraded by chondroclasts brought by vascular invasion (Vu et al., 1998). Moreover, 
the osteoclasts that are brought via vascular invasion further assist in the removal of cartilage matrix 
and this provides a scaffold for precursors of osteoblasts that also invade along with blood vessels to 
11 
 
differentiate and form the bone matrix within the site (Kronenberg, 2003) (Figure 8).  
 
vi. Osteoclast differentiation 
Osteoclasts are multinucleated, terminally differentiated cells that originate from mononuclear cells 
of the hematopoietic stem cell lineage (Florencio-Silva et al., 2015). Osteoclasts are the last cell type 
of the skeleton to appear during development and are responsible for bone resorption.  
The osteoclast differentiation pathway is common to that of macrophages and dendritic cells 
(Vaananen et al., 2000). The essential factors necessary for osteoclast differentiation are macrophage 
colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) (Boyle et 
al., 2003; Vaananen et al., 2000). Osteoclast precursors express M-CSF receptor, c-Fms, and RANKL 
receptor, RANK (Yamashita et al., 2012). In the presence of M-CSF and RANKL that are required to 
induce expression of gene including the lytic enzymes, cathepsin K and tartrate-resistant acid 
phosphatase (TRAP), osteoclast precursor cells are differentiated into mature osteoclasts (Boyle et al., 
2003).  
A breakthrough in the knowledge of the regulation of osteoclast differentiation was the 
identification of osteoprotegerin (OPG), secreted by osteoblasts and osteogenic stromal stem cell 
(Boyce and Xing, 2007; Boyle et al., 2003). Secreted OPG acts as a decoy receptor of RANKL to 
compete with RANK on the surface of osteoclast lineage cells and inhibits osteoclast formation and 
function (Yamashita et al., 2012). Thus, osteoblasts/stromal cells are involved in osteoclast 
differentiation as well as functions and OPG/RANKL/RANK regulatory axis is an important determinant 
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of osteoclast differentiation and thus bone resorption (Boyle et al., 2003).  
 
vii. Osteoclast functions 
Bone is the only tissue that contains a cell type, the osteoclast, that destroys the host tissue. 
Osteoclasts have an efficient machinery for dissolving crystalline hydroxyapatite and degrading 
organic mineralized bone matrix rich in collagen fibers (Vaananen et al., 2000). The unique structural 
features of osteoclasts that confer this efficient machinery are two domains that are in contact with the 
bone matrix: sealing zone and the ruffled border. Bone resorption only occurs when osteoclasts bind to 
the mineralized bone surface. Therefore, the first step of osteoclast activity is the formation of a tightly 
sealed bone attachment compartment called sealing zone. The primary adhesion mediating actin-rich 
structure of osteoclasts is known as podosomes (Luxenburg et al., 2007). Podosomes consist of a core 
of densely packed actin filaments and F-actin-associated proteins surrounded by integrins and 
attachment-related proteins (Itzstein et al., 2011). Then, due to intense trafficking of lysosomal and 
endosomal components, there is a formation of a highly convoluted ruffled border, an exit site to the 
resorption space (resorption lacunae) for protons and a number of enzymes including lysosomal 
protease called cathepsin K, that are necessary for the bone resorption (Roodman, 1991) (Figure 9). 
Particularly, bone resorption depends on a vascuolar-type proton ATPase (V-ATPase), located in the 
membrane of the ruffled border, and cathepsin K. V-ATPase mediates proton transport into resorption 
lacunae that acidifies resorption lacunae and dissolves inorganic hydroxyapatite minerals of bone 
matrix (Blair and Athanasou, 2004). The secretion of protons via V-ATPase by the ruffled border 
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causes exocytosis of cathepstin K, a cysteine protease, into resorption lacunae. Cathepsin K is 
responsible for the degradation of a major organic bone matrix, type I collagen (Inui et al., 1997; Wilson 
et al., 2009). Thus, the sealing zone determines the bone resorption site and the ruffled border serves 
as the actual bone resorbing organelle. 
As in the case of bone formation by osteoblasts, bone resorption is an energy demanding process. 
Glucose is the principal energy source required for osteoclasts and bone resorption is glucose 
concentration-dependent (Larsen et al., 2005; Williams et al., 1997).   
 
2. The Basic Principles of Bone Mass Control: Bone (Re) modeling 
The structural integrity of the skeleton is absolutely critical for vertebrates to survive because of its 
importance as a supportive framework of the body, mechanical protection of internal organs such as 
brain and for a wide range of movements. Furthermore, the bone marrow in the skeleton is the 
predominant site of hematopoiesis (Morrison and Scadden, 2014) and is essential for homeostatic 
control of the level of minerals in the blood because the skeleton contains more than 99% of the 
calcium, 80-90% of the phosphate and two thirds of the sodium in the body (Copp and Shim, 1963).  
In order for the skeleton to fulfill these functions throughout adulthood, the skeleton constantly 
renews itself through a process called bone modeling during childhood and bone remodeling during 
adulthood. Bone (re)modeling is characterized by bone resorption of pre-existing mineralized bone 
ECM by osteoclasts followed by de novo bone formation by osteoblasts (Takeda et al., 2003). Bone 
resorption and bone formation occur not only sequentially but also in a balanced manner to maintain 
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bone mass constant during adulthood (Wei and Ducy, 2010). Thus, any unbalance between bone 
resorption and bone formation causes skeletal disorders characterized either by a low or by a high 
bone mass (Takeda et al., 2003). For example, osteoporosis is the most frequent bone remodeling 
disease that is characterized by a relative increase in osteoclastic activity leading to a low bone mass 
and a high risk of fracture (Feng and McDonald, 2011; Takeda et al., 2003)   
The noteworthy feature of bone remodeling is that this process occurs constantly and 
simultaneously throughout the skeleton, that covers a large surface in the body, to insure its complete 
renewal and to maintain its structural integrity. Therefore, this process requires constantly a large 
supply of energy, mostly in the form of glucose, to bone cells, osteoblasts and osteoclasts.  
 
3. The Endocrine Functions of Bone 
Classically, the skeleton was viewed merely as an inert supportive framework in the body that is 
necessary for mobility, protection of internal organs, calcium homeostasis and maintenance of the 
hematopoietic niche. However, thanks to the advance of genetic approaches, knowledge regarding the 
functions of the skeleton has recently expanded beyond its role in the homeostatic regulation of bone 
mass. Advancement in genetic approaches allows scientists to systemically decipher the function of a 
gene of interest in vivo and to reveal hidden crosstalk between organs that influence each other. In 
other words, the whole-body organism analysis using genetic approach can further strengthen the 
fundamental principle of physiology: the mutual dependence between organs. Through genetic means, 
one additional yet unconventional function of the skeleton has been revealed: its endocrine function. It 
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has been apparent that the skeleton produces at least two hormones, fibroblast growth factor 23 
(FGF23) and osteocalcin (Ocn). Here, the several functions of these two hormones secreted by bone 
beyond the regulations of bone homeostasis are described.  
 
i. FGF23 
The first discovery that implicates bone as an endocrine organ has been the identification of 
FGF23 as a hormone secreted exclusively by osteoblasts and osteocytes, which are osteoblasts 
embedded in mineralized matrix in bone. FG23 regulates serum phosphate levels by altering levels of 
active vitamin D (1,25(OH)2D) and the activity of specific phosphate transporters in the kidney 
(DiGirolamo et al., 2012; Shimada et al., 2004). The serum levels of FGF23 increase and act 
physiologically to reduce serum phosphate and active vitamin D in response to increased serum levels 
of these molecules (Liu et al., 2006; Shimada et al., 2004). Accordingly, fgf23 null mice exhibited 
significantly high serum phosphate with increased renal phosphate reabsorption (Shimada et al., 2004). 
They also showed high serum active vitamin D that enhances intestinal phosphate absorption 
(Shimada et al., 2004). These phenotypes seen in fgf23-/- mice are the mirror image of what is seen in 
human patients with hypophosphatemia disorders caused by a primary increase in the serum levels of 
FGF23. These disorders includes TIO (Tumor-Induced Osteomalacia) and ADHR (Autosomal 
Dominant Hypophosphatemic Rickets) in which fgf23 was identified as responsible gene (Fukumoto 
and Martin, 2009; Shimada et al., 2001; White et al., 2000).   
Altogether, genetic and clinical studies have shown that abnormal levels of the bone derived 
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hormone FGF23 alter phosphate and vitamin metabolism.  
 
ii. Osteocalcin  
A more surprising new dimension of physiological functions of the skeleton was uncovered after 
the identification of osteocalcin (Ocn), secreted exclusively by osteoblasts, as a multifunctional 
hormone. Osteocalcin is the most abundant non-collagenous protein in bone ECM and contains 46-50 
amino acid residues that undergo post-translational modification of three glutamic acid residues (GLA 
residues) by vitamin K-dependent γ-carboxylation before its secretion from osteoblasts (Hauschka et 
al., 1989). This post-translational modification of osteocalcin is essential for calcium and 
hydroxyapatite binding and allows deposition of osteocalcin in bone ECM (Razzaque, 2011). On the 
contrary, undercarboxylated osteocalcin, formed as a result of post-translational modification, have a 
low affinity for hydroxyapatite and is more easily released in to the blood circulation (Razzaque, 2011).  
Osteocalcin was thought to play a role solely in bone biology due to its confined expression in 
osteoblasts. However, surprisingly, Ocn deletion resulted in mice in which bone mineralization was 
normal but that were abnormally docile and fatty. Ocn-/- mice also bred poorly. In addition to those 
unexpected phenotypes seen in Ocn-/- mice, there are several clinical and experimental observations 
that support the hypothesis that the bone is an endocrine organ. 
First, as described above, the skeletal biology suggests that bone remodeling is metabolically 
demanding process. Therefore it has been hypothesized that there is a coordinated regulation of bone 
mass and energy metabolism (Karsenty, 2006) and clinical observations support this notion. For 
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instance, when food intake is decreased during childhood, there is an arrest of growth; when this 
situation develops in adults, there is bone loss (Wei and Karsenty, 2015).  
Secondly, clinically, it is well-known that the sex steroid hormones are one of the powerful 
hormonal regulations of bone remodeling necessary to maintain skeletal integrity (Khosla et al., 2001; 
Nakamura et al., 2007). Since the fundamental principle of whole-body physiology is mutual 
dependence of organs, it has been suggested that bone may in turn affect reproductive functions.  
Lastly, in another view of skeletal biology, leptin, a hormone secreted primarily by adipocytes and 
regulating appetite and gonadal function, inhibits bone mass accrual by signaling in brainstem neurons 
to prevent the synthesis of serotonin (Friedman and Halaas, 1998; Oury et al., 2010; Takeda et al., 
2002; Yadav et al., 2009). The identification of the brain as a determinant of bone mass accrual raises 
the question whether bone in turn signals back to the brain. 
Indeed, several extensive genetic studies in mice and humans have proved that osteocalcin once 
activated as a hormone by undercarboxylation, influences glucose metabolism, male fertility and brain 
development and functions (Ferron et al., 2010a; Lee et al., 2007; Oury et al., 2013c; Oury et al., 2011) 
(Figure 10). Specifically, genetic as well as molecular studies have verified that osteocalcin promotes 
glucose homeostasis by acting on pancreatic β-cells to increase their proliferation as well as insulin 
secretion and to favor insulin sensitivity in both muscle and white adipose tissues (Ferron et al., 2010a; 
Lee et al., 2007). Furthermore, osteocalcin also favors testosterone production by the Leydig cells of 
the testis and thereby regulate male fertility (Oury et al., 2011). Recently, a study has shown that the 
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spectrum of osteocalcin functions even extends to brain development and cognition. Specifically, 
osteocalcin enhances postnatal neurogenesis and prevents anxiety as well as depression and also 
favors memory. Furthermore, maternal osteocalcin favors brain development of the fetus and affects 
their cognition postnatally (Oury et al., 2013c). These results showed that bone does signal back to 
brain and shed a light on a crosstalk between bone and brain.  
Altogether, the multifunctional role of osteocalcin secreted exclusively by osteoblasts revealed that 
bone is a true endocrine organ. Yet, all of the functions of osteocalcin as well as its target tissues/cells 
are not fully discovered and further studies on the impact of osteocalcin signaling on whole-body 
physiology will further reveal the physiological importance of the skeleton as an endocrine organ.  
 
4. Integration of Bone Remodeling and Glucose Metabolism by Insulin Signaling   
An important feature of osteocalcin biology is that, to act as a hormone, osteocalcin needs to be 
undercarboxylated before reaching the blood stream. In vitro as well as in vivo studies showed that  
only the undercarboxylated form of osteocalcin (GLU13 is not carboxylated) indeed is the active form 
of the hormone (Ferron et al., 2008; Ferron et al., 2015; Karsenty and Ferron, 2012; Oury et al., 2011). 
Given that protein decarboxylation is known to occur only in an acidic pH, it was hypothesized that 
bone resorption, whose acidification process occurs at a low pH in resorption lacunae (pH4.5), may be 
involved in the activation of osteocalcin. In other words, the endocrine function of the skeleton may 
also require the coordinated actions of both osteoblasts and osteoclasts.  
 In addition, as osteocalcin secreted by osteoblasts as a regulator of insulin secretion, several 
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observations have led to the hypothesis that insulin signaling in osteoblasts in return regulates the 
activation of osteocalcin. This hypothesis was raised mainly based on the fact that Ocn is not the only 
gene that affects glucose homeostasis in osteoblasts. Indeed the deletion of Esp, a gene encoding 
osteoblast testis-specific protein tyrosine phosphatase (OST-PTP), results in mice that display a mirror 
image of what is observed in Ocn-/- mice (Lee et al., 2007). Importantly, the mice in which Esp was 
deleted either globally or specifically in osteoblast exhibited the same phenotype. Specifically, they 
were hypoglycemic, hyperinsulinemic and the serum fraction of undercarboxylated osteocalcin was 
significantly higher than in control mice (Lee et al., 2007). Given that osteocalcin is not phosphorylated, 
this raised the question what is the substrate of OST-PTP that influences the activity of osteocalcin. 
Since OST-PTP is a tyrosine phosphatase, the insulin receptor (InsR) in osteoblasts was hypothesized 
to be a target of OST-PTP since InsR activity is often inhibited by protein tyrosine phosphatase 
(Schlessinger, 2000). Furthermore, investigation of insulin signaling in osteoblasts was more relevant 
since mice lacking the insulin receptor (InsR) in two classical insulin target organs, skeletal muscle and 
white adipose tissue (WAT), did not display glucose intolerance thus implicating that insulin must act in 
additional tissue to achieve glucose homeostasis (Bluher et al., 2002; Bruning et al., 1998).  
Here, the contribution of osteoclasts to the endocrine function of the bone and the importance of 
insulin signaling in osteoblasts to integrate bone remodeling and glucose metabolism by promoting 
activation of osteocalcin are described.  
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i. Insulin signaling in osteoblasts integrates bone remodeling and glucose homeostasis 
The insulin Receptor (InsR) is a tyrosine kinase that can be activated by its conformational 
changes upon insulin binding that induces auto-phosphorylation required for the kinase activity and 
inactivated by phosphotyrosine-specific phosphatases (Kasuga et al., 1983; Siddle, 2011; Wilden et al., 
1992). Molecular and genetic studies have identified that a tyrosine phosphatase OST-PTP encoded 
by a gene named Esp dephosphorylates and inactivates the InsR in osteoblasts (Ferron et al., 2010a). 
Genetic studies further confirmed that insulin signaling in osteoblasts indeed is necessary for the 
regulation of glucose homeostasis. Specifically, the metabolic phenotype of the mice lacking the InsR 
(InsRosb-/-) in osteoblasts was similar to the one of Ocn-/- mice. They were glucose intolerant and 
insulin insensitive and had significantly less active osteocalcin in serum. Accordingly, double 
heterozygous compounds for InsR and Ocn (InsRosb+/-;Ocn+/-) displayed metabolic abnormalities 
similar with Ocn-/- mice. In contrast, removing one allele of InsR from Esp-/- mice (InsRosb+/-;Esp-/-) 
normalized the metabolic abnormalities of the Esp-/- mice. Thus, these genetic studies verified that 
insulin signaling in osteoblasts is a determinant of osteocalcin bioactivity (Ferron et al., 2010a; Lee et 
al., 2007). The important question was how insulin signaling acts in osteoblasts to favor activation of 
osteocalcin and regulate whole-body glucose homeostasis. It was revealed that insulin signaling takes 
advantage of the osteoblast ability to promote bone resorption by decreasing the expression of Opg, 
an inhibitor of osteoclast differentiation. The decrease in Opg expression in osteoblasts promotes bone 
resorption resulting in an acidification of bone ECM (pH 4.5) that activates osteocalcin by 
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decarboxyation of one glutamic residue GLU13 (Ferron et al., 2010a; Karsenty and Ferron, 2012) 
(Figure 11). Altogether, these observations showed that there is a feed-forward regulation between 
insulin and osteocalcin and that insulin signaling integrates bone remodeling to maintain glucose 
homeostasis by favoring the activation of osteocalcin.  
 
ii. Insulin signaling in osteoblasts and osteocalcin activity in Human 
Recent clinical investigations support the notion that osteocalcin is also involved in the 
regulation of glucose homeostasis in humans. For example, serum osteocalcin concentration is 
inversely associated with blood markers of abnormal metabolic phenotype and the active form of 
osteocalcin stimulates insulin production and promotes β-cell mass and function in human subjects in 
most studies (Hwang et al., 2009; Kanazawa et al., 2009; Pittas et al., 2009; Sabek et al., 2015). The 
importance of osteocalcin signaling in human is further confirmed by the fact that two individuals with 
the missense mutation in GPRC6A, a receptor mediates osteocalcin signaling in β-cells as well as in 
the Leydig cells, displayed glucose intolerance (Oury et al., 2013a). In addition, studies have identified 
that PTP1B, tyrosine phosphatase in human osteoblasts, fulfills the same functions as OST-PTP in 
mouse osteoblasts. As seen in mouse studies, insulin signaling in human osteoblasts is regulated by 
PTP1B and favors bone resorption by regulating the expression of Opg and this notion is further 
implied in osteopetrotic patients and mice showed the increase in osteocalcin carboxylation and 
decrease in insulin blood levels (Ferron et al., 2010a). Altogether, these studies confirmed that 
osteocalcin activity indeed is associated with glucose homeostasis and is in part determined by bone 
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resorption regulated by insulin signaling in osteoblasts in human.  
 
iii. Pathogenic contribution of insulin resistance in bone to glucose homeostasis 
The question raised by the contribution of insulin signaling in osteoblasts to whole-body 
glucose homeostasis in mice fed a normal diet was whether bone contributes to the insulin resistance 
that develops in mice fed a high-fat diet (HFD). Indeed, in mice fed a HFD, the circulating levels of the 
active form of osteocalcin are significantly lower than in control mice. This leads to a decrease in 
insulin secretion and sensitivity (Wei et al., 2014a; Wei and Karsenty, 2015). Biochemical studies have 
revealed that insulin resistance develops in bone as a result of an increase in circulating levels of free 
saturated fatty acids that enhances the E3 ubiquitin ligase Smurf1-mediated loss of InsR accumulation 
in osteoblasts. Specifically in osteoblasts, the increase in circulating level of free saturated fatty acids 
upregulates Smurf1 expression that favors the degradation of the InsR. This molecular mechanism 
explained how insulin resistance in bone affects whole-body glucose homeostasis. However, despite 
its significant role in regulating InsR accumulation in osteoblasts, the metabolic phenotype of Smurf1-/- 
mice has never been investigated in vivo. Thus, the functions of Smurf1 in osteoblasts may extend 
beyond osteoblast differentiation and bone formation since by favoring the degradation of the InsR in 
osteoblasts, Smurf1 could be a regulator of circulating osteocalcin levels in vivo.  
Overall, these genetic and biochemical observations suggest that insulin resistance in bone 
develops as a result of loss of InsR mediated by Smurf1 upon increase in the circulating level of free 
saturated fatty acids. Clinically, along with the importance of osteocalcin and insulin signaling in 
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osteoblasts for glucose homeostasis in human, they further suggest in a pathological situation that 
bone contributes to whole-body glucose homeostasis (Oury et al., 2013a; Wei et al., 2014a).  
 
5. Glucose Uptake in Bone Cells  
The identification of the crosstalk between insulin signaling and bone to regulate glucose 
homeostasis (Ferron et al., 2010a) raised a fundamental question: why does bone regulate 
whole-body glucose homeostasis in the first place? It can be hypothesized that glucose may be 
important for bone remodeling and particularly that the development and functions of osteoblasts and 
osteoclasts characterizing bone remodeling is intimately linked to glucose homeostasis.  
Glucose indeed is the major source of energy in most living cells for development and growth. 
Most mammalian cells, including osteoblasts and osteoclasts, are dependent on a continuous supply 
of glucose, as a source for adenosine 5’ triphosphate (ATP) synthesis, ribose 5 phosphate for nucleic 
acid synthesis and NADPH for reductive biosynthetic process. Furthermore, there is an emerging 
concept suggesting that glucose is not only a source of energy but also acts as signaling molecules 
and exerts transcriptional control in the cells (Mobasheri, 2012). Yet, the crosstalk between metabolic 
pathways and bone development and functions is largely unexplored. 
In mammalian cells, glucose is not freely permeable across the lipid bilayer. Glucose enters across 
mammalian cells through members of the GLUT/SLC2A family of facilitative sugar transporters and the 
SGLT/SLC5A family of Na+ dependent active sugar transporters (Gould and Holman, 1993; Wood and 
Trayhurn, 2003). SGLT has a limited tissue expression and the Na+ dependent active transportation of 
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glucose (and galactose) by SGLT is found to be taking place across the luminal membrane of cells 
lining the small intestine and the proximal tubules of the kidney (Wood and Trayhurn, 2003). On the 
other hand, GLUTs encoded by the SLC2 genes are found in various tissues and cell types (Mueckler 
and Thorens, 2013). Despite the importance of glucose transport into cells and the knowledge that 
bone remodeling is a metabolically demanding process, there is limited published information which 
GLUT transporter(s) play(s) a major role in glucose uptake occurs in bone cells. 
 Here, the basic knowledge of structural feature of GLUT family is discussed.  
 
i. The GLUT family 
GLUT proteins are facilitative transporters utilize the diffusion gradient of glucose across plasma 
membranes (Wood and Trayhurn, 2003). The GLUT family can be divided into three classes: Class I 
(GLUTs 1-4 ), Class II (GLUTs 5,7,9 and 11) and Class III (GLUTs 6,8,10,12 and HMIT (H+-coupled 
myo-inositol transporter))(Joost et al., 2002) (Figure 12). The class I facilitative transporters are the 
best characterized glucose transports and they can be distinguished on the basis of their specific 
tissue expression. For instance, GLUT1 is ubiquitously expressed with particularly high levels in 
erythrocytes and in the endothelial cells lining the blood vessels of the brain. GLUT2 is a low-affinity 
glucose transporter in liver, intestine, kidney and pancreatic beta cells. GLUT3 is expressed in neurons. 
GLUT1 and GLUT3 allow glucose to cross the blood brain barrier and enter neurons. Importantly, 
GLUT4 is only insulin-sensitive transporter and is found in heart, skeletal muscle and adipose tissues 
(Joost et al., 2002; Thorens and Mueckler, 2010). Class II is comprised of the fructose-specific 
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transporters and Class III is characterized by the lack of glycosylation site in the first extracellular linker 
domain (Joost et al., 2002). 
Despites the extensive characterization of GLUTs, it still remains unclear how glucose uptake 
occurs in bone cells and what cellular functions will be affected upon disruption of glucose uptake 
during development and in postnatal life. Yet, there are a few studies indicating the involvement of 
GLUT1 in human and rodent osteoblastic cell lines (Thomas et al., 1996; Zoidis et al., 2011). Clinically, 
the importance of glucose uptake in bone development is also suggested since children chronically fed 
a ketogenic diet experience poor longitudinal growth (Groesbeck et al., 2006). Thus, answering these 
questions would be critical to improve our knowledge of the biological importance of the proper inflow 
of glucose as a main nutrient to bone cells to link bone remodeling and glucose metabolism. 
 
6. AMPK and Osteoblasts  
Given the possible link between glucose metabolism and bone development described above, 
bone cells must have a mechanism to regulate their cellular activity when faced with nutrient 
fluctuations in the extracellular environment. In general, although ATP is mainly generated from ADP 
by the mitochondrial ATP synthase, all eukaryotic cells contain adenylate kinase, which produces AMP 
and ATP from 2 ADP (2ADP AMP+ATP) (Hardie et al., 2012). Thus, when ATP is consumed, the 
relative increase in AMP concentration is much greater than that of ADP. Therefore, a key signal of 
nutrient fluctuations in the extracellular environment is changes in the concentration of AMP. Based on 
this fact, it seems logical that cells have a means to monitor AMP/ATP ratio. Indeed, AMP-activated 
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protein kinase (AMPK) is known to be the principal energy sensor in most cells and acts as a guardian 
of maintenance cellular energy homeostasis (Hardie, 2007; Hardie et al., 2012). Here, the structural 
and functional features of AMPK and its putative role in bone cells are described.  
 
i. Structural and functional features of AMPK 
AMPK exists as heterotrimeric complexes comprising a catalytic α subunit and regulatory β 
and γ subunits (Hardie et al., 2012). AMPK is activated by energy stress causing depletion of ATP and 
elevated cellular level of AMP or ADP (Hardie et al., 2012). Once activated, AMPK maintains energy 
homeostasis by phosphorylating downstream targets at Ser/Thr residues within a characteristic 
sequence motif. This results in activation of catabolism to generate ATP and inhibition of a number of 
energy consuming pathways including protein, carbohydrate and lipid biosynthesis as well as cell 
growth and proliferation (Hardie, 2007; Hardie et al., 2012) (Figure 13).  
Here, among a number of regulatory mechanisms that AMPK exerts, particularly, regulation of 
protein synthesis through AMPK regulation of mTORC1 is described.   
 
ii. Regulation of protein synthesis by mTORC1 and AMPK 
The mammalian target of rapamycin complex 1 (mTORC1) signaling pathway integrates both 
intracellular and variety of extracellular signals and serves as a central regulator of mRNA translation, 
and therefore protein synthesis (Mahoney et al., 2009). mTORC1 has five components: mTOR, which 
is the catalytic subunit of the complex; regulatory-associated protein of mTOR (Raptor); mammalian 
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lethal with Sec13 protein 8 (mLST8); proline rich AKT substrate 40 kDa (PRAS40); and 
DEP-domain-containing mTOR-interacting protein (Deptor) (Laplante and Sabatini, 2009; Peterson et 
al., 2009). mTORC1 positively controls protein translation by phosphorylating downstream targets, 
eukaryotic initiation factor 4E (elF4E)-binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase 
(S6K) that mediates protein translation (Schmelzle and Hall, 2000). One of the associated proteins in 
mTORC1 complex, the Raptor, acts as a scaffold to recruit 4E-BP1 and S6K to the mTORC1 (Gwinn et 
al., 2008). It is also known that tuberous sclerosis complex (TSC) tumor suppressors, TSC1 and TSC2, 
are critical upstream inhibitors of the phosphorylation of S6K and 4EBP1, thus of mTORC1 complex 
(Gwinn et al., 2008; Inoki et al., 2003).  
Nutrient status, is signaled to mTORC1 through AMPK-mediated regulation (Laplante and Sabatini, 
2009). Specifically, there are two modes of AMPK mediated inhibition of mTORC1 activity.  First, 
TSC2 is regulated by AMPK-dependent phosphorylation and plays an essential role in regulating 
mTOC1 activity in response to the cellular energy status (Inoki et al., 2003). Specifically, TSC2 
contains a GTPase activation protein (GAP) domain that inactivates the Rheb GTPase that directly 
activates the mTORC1 complex in vitro (Sancak et al., 2007). Upon energy stress, AMPK is activated 
and phosphorylates TSC2 which increases the GAP activity of TSC2 towards Rheb and reduces 
mTORC1 activity (Inoki et al., 2003).  Additionally, AMPK can reduce mTORC1 activity in response to 
energy depletion by directly phosphorylating Raptor on two well-conserved serine residues (Gwinn et 





iii. Perspective: The role of AMPK in osteoblast differentiation and functions 
AMPK, which is a major mediator of energy sensing mechanisms, is expressed ubiquitously. 
However, even though some studies have implicated the involvement of AMPK in bone, how AMPK 
exerts its effect on bone cells during development and in postnatal life is poorly defined. In addition, 
mice lacking AMPK specifically in osteoblasts or osteoclasts have not yet been generated and 
analyzed. Thus, it is critical to study the physiology of mice lacking AMPK specifically in bone cells to 
determine the functions of AMPK in vivo during development and in postnatal life. Investigating how 
AMPK regulates osteoblasts and/or osteoclasts function upon energy stress requires the identification 
of the downstream targets of AMPK in bone cells that provide a significant insight into the link between 










Figure 1. Intramembranous ossification. 
Schematic illustration of intramembranous ossification during development. The cells of the 
mesenchymal condensations differentiate directly into bone-forming osteoblasts. Modified from (Ornitz 





Figure 2. Alcian blue/alizarin red staining of WT and Runx2-/- embryos at embryonic day (E) 
16.5.  
Alcian blue stains cartilage (blue) and alizarin red stains mineralized bone (red). The mineralized bone 
is completely absent in Runx2-/- embryo (b) even though the mineralized bone is present in WT 





Figure 3. Alcian blue/alizarin red staining of newborn WT and Runx2+/- mice.  
Alcian blue/alizarin red staining of clavicles and skulls of WT (a) and Runx2+/- (b) newborn mice. 
Runx2+/- mouse displays cleidocranial dysplasia characterized by open fontanelles and short clavicles. 





Figure 4. Alcian blue/alizarin red staining of 10-day-old WT and Twist-1 +/- mice.  
Alcian blue/alizarin red staining of skulls of 10-day-old WT (a) and Twist-1+/- (b) mice. Twist-1+/- 






Figure 5. Spatial and temporal expression of α1(I) Collagen and Runx2 in hind limbs during 
development. 
In situ hybridization analysis of α1(I)Collagen (a-b), Runx2 (c-d) in hind limbs at E10.5 and E12.5. 





Figure 6. Enzymatic cascade for protein ubiquitination. 
The ubiquitination cascade involves the successive actions of three types of enzymes: E1 
ubiquitin-activating enzymes that recruits ubiquitin (Ub), E2 ubiquitin-conjugating enzymes that 
transfers the ubiquitin to the targeted protein via E3 ubiquitin ligases that recognize substrate protein. 





Figure 7. Domain architectures of Smurf1.  
Smurf1 contains a catalytic HECT domain in the C-terminal, two WW domains (WW1 and WW2) and a 





Figure 8. Endochondral ossification.  
Schematic illustration of endochondral ossification during development. The cells of mesenchymal 
condensation (red) are differentiated into chondrocytes expressing type II collagen (blue). Then, the 
innermost chondrocytes become hypertrophic and express α1(X) collagen (purple). Once chondrocyte 
hypertrophy is initiated, cells in perichondrium start to differentiate into osteoblasts (yellow). The final 
step is vascular invasion and the formation of a center of ossification containing type I 





Figure 9. The structural features of osteoclasts.   
Schematic view of a bone-resorbing osteoclast. Two domains of osteoclasts, sealing zone (red) and 
ruffle border (green), are in contact with the bone matrix. Acidification of bone ECM by secretion of 
proton (H+) results in the activation of cathepsin K, that is responsible for the degradation of a major 
organic bone matrix, type I collagen (Boyle et al., 2003; Vaananen et al., 2000). Modified from (Boyle et 





Figure 10. Bone-derived hormone osteocalcin regulates several organs. 
Schematic illustration of the multifunctional roles of osteocalcin. Undercarboxylated (active) 
osteocalcin favors insulin secretion and β-cell proliferation in the pancreas, energy expenditure and 
insulin sensitivity in muscle, liver and white adipose tissue (WAT), male fertility by stimulating 
testosterone synthesis and brain development and memory. Modified from (Karsenty and Ferron, 





Figure 11. Insulin signaling in osteoblasts regulates of osteocalcin activation via bone 
resorption 
Insulin signaling in osteoblasts is regulated by Esp and promotes bone resorption by decreasing the 
expression of Opg, an inhibitor of osteoclast differentiation. The acidification of bone ECM (pH 4.5) 
activates osteocalcin by decarboxyation. As a result, the active form of osteocalcin promotes insulin 





Figure 12. Dendrogram of the glucose transporter GLUT family. 
The GLUT family can be divided into three classes depicting sequence similarities: Class I, Class II 






Figure 13. Regulation of energy metabolism by AMPK  
AMPK is activated by elevated cellular level of AMP and/or ADP. Once activated, AMPK maintains 
energy homeostasis by activation of catabolic pathways to generate more ATP and by inhibition of a 
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The synthesis of Type I collagen, the main component of the bone matrix, precedes the expression of 
Runx2, the earliest determinant of osteoblast differentiation. We hypothesized that the osteoblasts’ 
energetic needs might explain this apparent paradox. We show here that glucose, the main nutrient of 
osteoblasts, is transported in these cells through Glut1 whose expression precedes that of Runx2. 
Glucose uptake favors osteoblast differentiation by suppressing the AMPK-dependent proteasomal 
degradation of RUNX2 and promotes bone formation by inhibiting another function of AMPK. While 
RUNX2 cannot induce osteoblast differentiation when glucose uptake is compromised, raising blood 
glucose levels restores collagen synthesis in Runx2-null osteoblasts and initiates bone formation in 
Runx2-deficient embryos. Moreover, RUNX2 favors Glut1 expression, and this feed-forward regulation 
between RUNX2 and Glut1 determines the onset of osteoblast differentiation during development and 
the extent of bone formation throughout life. These results reveal an unexpected intricacy between 




Introduction   
The transcription factor RUNX2 is a master determinant of osteoblast differentiation (Karsenty et al., 
2009; Long, 2012). Its expression in prospective osteoblasts precedes osteoblast differentiation, its 
inactivation prevents osteoblast differentiation and its haplo-insufficiency causes a skeletal dysplasia 
called cleidocranial dysplasia (CCD) that is characterized by a delay in osteoblast differentiation 
leading to hypoplastic clavicles and open fontanelles. Several aspects of RUNX2 biology remain 
however poorly understood. For example, the nature of the molecular events leading to RUNX2 
accumulation in cells of the osteoblast lineage is largely unknown. A second question is to determine if 
and how RUNX2 contributes to bone formation by differentiated osteoblasts. A peculiar feature of 
osteoblast biology raises this latter issue. 
Type I collagen is by far the most abundant protein of the bone extracellular matrix (ECM) and its 
synthesis by osteoblasts is often considered a biomarker of bone formation. Type I collagen is a 
heterotrimeric protein made of two α1(I) chains and one α2(I)chain that are encoded by two different 
genes (Vuorio and de Crombrugghe, 1990). In vitro, RUNX2 can bind to and up-regulate the activity of 
a α1(I)Collagen promoter fragment (Kern et al., 2001). In vivo, however, Type I collagen synthesis 
precedes Runx2 expression in prospective osteoblasts. Thus, the regulation of Type I collagen 
synthesis in osteoblasts is not fully understood, and by extension since the bone ECM is mainly made 
of Type I collagen, it is also unclear how bone formation by osteoblasts is regulated.  
Besides being responsible of bone formation, the osteoblast is an endocrine cell that secretes a 
hormone, osteocalcin that favors glucose homeostasis (Lee et al., 2007). Notwithstanding the 
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molecular complexity of this emerging regulation, the identification of bone as a regulator of glucose 
metabolism raises a fundamental question: why would bone have this role? A prerequisite to 
answering this question is to define the functions of glucose in osteoblasts. 
Here we asked if the energetic needs of the osteoblast might explain how osteoblast differentiation and 
bone formation occurs in vivo. We found that glucose is the main nutrient of osteoblasts and it is 
transported in these cells in an insulin-independent manner through the facilitative Glut1 glucose 
transporter whose expression precedes that of Runx2 during skeletogenesis. By inhibiting one activity 
of AMPK, glucose is necessary for RUNX2 accumulation and osteoblast differentiation; through the 
inhibition of another AMPK function glucose is necessary for collagen synthesis and bone formation. 
Moreover, by promoting RUNX2 accumulation, glucose uptake in osteoblasts favors Osteocalcin 
expression and whole-body glucose homeostasis. We further show that RUNX2 is not sufficient for 
timely osteoblast differentiation and proper bone formation if glucose uptake is compromised whereas 
raising blood glucose levels induces collagen synthesis and bone formation in the absence of Runx2. 
The relationship between RUNX2 and glucose uptake is even more elaborate since RUNX2 is needed 
for Glut1 expression in osteoblasts. This crosstalk between RUNX2 and glucose uptake acts as an 
amplification mechanism allowing osteoblast differentiation and bone formation to be coordinated 
throughout life. This study provides a bone-centric illustration of the importance of the crosstalk 




Materials and Methods 
Mice generation 
To generate Glut1fl/+ mice, a targeting vector harboring 2 LoxP sites flanking exon 3-10 of Glut1 was 
electroporated into ES cells (CSL3,129/SvEvTac) (Figure S2A). Targeted ES cells were detected by 
southern blots and injected in 129Sv/EV blastocysts to generate chimeric mice. Chimeric mice were 
crossed with Gt(ROSA)26Sor
tm1(FLP1)Dym
 mice to remove the Neomycin resistance cassette and to 
generate Glut1fl/+ mice. Glut1fl/+ mice were then crossed with Dermo1-Cre(Yu et al., 2003), 
Osterix-Cre (Rodda and McMahon, 2006) or Ocn-Cre mice (Zhang et al., 2002) to generate Glut1osb+/- 
mice, whose progenies were intercrossed to obtain Glut1dermo1−/−, Glut1osx−/− and Glut1ocn−/− mice, 
respectively. To generate α1(I)Col-Glut1 transgenic mice, a cDNA fragment of the mouse Glut1 was 
cloned into a plasmid containing a 2.3-kb α1(I) collagen promoter and microinjected using standard 
protocol. Ampka1fl/fl mice were obtained from The Jackson Laboratory (Nakada et al., 2010). 
Runx2fl/fl mice were generated as previously described (Takarada et al., 2013). Shn3+/- and 
Smurf1+/- mice were generous gifts of Dr. L. Glimcher (Weill Cornell Medical College) and Dr. J. Wrana 
(U of Toronto, Canada) respectively (Jones et al., 2006; Narimatsu et al., 2009). Except for 
α1(I)Col-Glut1 mice, which had been backcrossed to C57 background 5 times, all other mice analyzed 
were maintained on a C57/129 mixed background. Control littermates were analyzed in all 
experiments. All procedures involving animals were approved by CUMC IACUC and conform to the 





Mouse calvaria osteoblasts were isolated and cultured as described previously (Ducy and Karsenty, 
1995). Osteoclast precursors (monocytes) were isolated by culturing bone marrow cells with 
αMEM/10% FBS containing M-CSF (10 ng/mL) for 6 days and then treated with RANKL (30 ng/mL) and 
M-CSF (10 ng/mL) for 7 days. C2C12 myoblasts (ATCC), mHippoE-14 embryonic mouse hippocampal 
hypothalamic cell Line (Cellutions biosystems) and COS-7 cells were cultured in DMEM/10% FBS. 
Glut1-/-, Raptor-/-, Runx2-/-, Glut1-/-;Ampka1+/-, Glut1-/-;Ampka1-/-, Ampka1+/- and Ampka1-/- 
calvaria osteoblasts were generated by infecting Glut1fl/fl, Raptorfl/fl, Runx2fl/fl, Glut1fl/fl;Ampka1fl/+, 
Glut1fl/fl;Ampka1fl/fl, Ampka1fl/+ or Ampka1fl/fl osteoblasts with either empty vector or Cre-expressing 
adenovirus (1:800 MOI) (University of Iowa). SiRNAs against Tsc1 and Tsc2 (Dharmacon) were 
transfected to primary osteoblasts according to manufacturer’s protocol. 
 
Oxygen consumption rate measurements 
Cells were seeded in XF96 plates at 20,000 cells/well. The next day, the cells were incubated with 1X 
KHB buffer (111mM NaCl, 4.7mM KCl, 2mM MgSO4 and 1.2mM Na2HPO4) supplemented with 
vehicle, 10 mM glucose, 2mM Glutamine or 100M palmitate and further incubated in CO2-free 
incubator at 37°C for 2 hour. Oxygen consumption rate was then analyzed using XF24 Extracellular 
Flux Analyzer (Seahorse
TM
 bioscience) and normalized to DNA concentrations. 
Euglycemic clamps  
Euglycemic clamps were conducted in conscious mice following a 12hrs fasting with a continuous 
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infusion of isotonic saline or human insulin (2.5 mU/kg/min) and a variable infusion of 25% glucose to 
maintain glucose at 150 mg/dl. To assess tissue-specific glucose uptake, 2-deoxy-d-[1-
14
C]glucose 
(PerkinElmer Life Sciences) was administered as a bolus (30 μCi, 287mCi/mmol) 75 minutes after the 
start of the clamp (Zong et al., 2009). In details, at 4~5 days before clamping experiments, mice will be 
implanted with catheters into the jugular vein and carotid artery using aseptic technique. Following 
overnight fast (14-hour), D-[3-
3
H]glucose (0.05 μCi/min) will be infused using microdialysis pumps 
through the intravenous catheter in the animal for 2 hours to assess basal rate of whole-body glucose 
turnover. A blood sample (60 μl) will be collected at the end for the measurement of plasma glucose, 
insulin, and [
3
H]glucose concentrations (basal parameters). For each blood sample taken, an equal 
volume of mouse blood will be infused to prevent stress from volume depletion. Following the basal 
period, a 2-hr euglycemic clamp will be conducted with continuous infusion of either 1xPBS (basal 
condition without insulin) or human insulin at a rate of 4mU/kg/min (Hyperinsulinemic condition). Blood 
samples (20 μl) will be collected at 10~20 min intervals for the immediate measurement of plasma 
glucose (20, 40, 60, 80, 90, 100, 110 and 120 min of clamps). A 20% glucose solution will be infused at 
variable rates to maintain basal glucose levels (~5 mM). Insulin-stimulated whole-body glucose 
metabolism will be estimated with a continuous infusion of [
3
H]glucose throughout the clamps (0.1 





be administered as a bolus (30 μCi/ 287mCi/mmol) at 75 min after the start of clamp. Blood samples 









C]DG concentrations. Additional blood samples (50 μl) will be taken at 120 
min to measure plasma insulin concentrations (clamp parameters). At the end of clamp, mice will be 
anesthetized and tissue samples (gastrocnemius, tibialis anterior, and quadriceps from both hindlimbs, 
epididymal white adipose tissue, liver, tibia and femurs of both legs) isolated for measuring 2-[
14
C]DG 
content and molecular analysis. 
 
Glucose consumption and uptake assay 
For glucose consumption measurements, following 16-hr incubation with osteoblasts, glucose 
concentration in the culture medium was assayed with Glucose Assay Kit (Biovision). Glucose uptake 
was determined by the uptake rate of 2-[U-
14
C] deoxyglucose (2-DG) in cells.  Following 1hr fast in 
glucose free KRH buffer (50mM HEPES pH7.4, 136mM NaCl, 4.7mM KCl, 1.25mM MgSO4, 1.25mM 
CaCl2 and 0.1% BSA), cells were cultured in KRH buffer containing 100M 2-deoxyglucose and 
0.5Ci/ml 2-
14
C-DG (287mCi/mmol, Perkin Elmer, NEC495A) for 1hr.  For glucose uptake in bones, 
10Ci of 2-
14
C-DG were IP injected in mice at random feed state for 1h calvariae were then collected 
for analysis. The amount of 2-
14
C-DG in total cell or bone lyses was quantified by liquid scintillation 
counter (WALLAC 1409) and normalized to protein content (Bio-Rad).  
 
Molecular biology and biochemistry 
For quantifying gene expression, RNA samples were extracted using TRIZOL reagent (Invitrogen). 
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One to 2 g of total RNA was converted into cDNA using M-MLV reverse transcriptase (Invitrogen). 
QPCR analyses were performed using CFX-Connect realtime PCR system (Bio-Rad). Relative 
expression levels of each gene were normalized to the levels of 18S ribosomal RNA or β-actin. 
Western blot analyses were carried out using standard protocol. All antibodies were obtained from Cell 
Signaling Technology, except the anti-GLUT1 (EMD Millipore), anti-COL1A1, anti-RUNX2, 
anti-SMURF1 (Santa Cruz), anti-Phospho-Ser148 SMURF1 (Genescript) and anti--ACTIN (Sigma). 
Quantification of Western blots was performed using Image J. Protein levels were quantified and 
normalized to ACTIN or GADPH levels. Relative protein levels were calculated with respect to control 
samples. All western blot experiments were repeated at least three times, with different samples. 
 
Glycogen assay 
After cultured in differentiation medium for 14 days, osteoblasts were homogenized in dH2O and 
incubated in boiling water for 5 mins to inactive enzymes. Fifty microliter of lyses was used for 
glycogen assay (BioVision Inc,) according to manufacturer’s protocol. Glycogen content was then 
normalized to protein concentration.  
 
Skeleton preparation, Bone histology and in situ hybridization 
Skeleton preparations and Alcian blue/alizarin red staining were carried out according to standard 
protocols (McLeod, 1980). Bone histology analyses including Von Kossa staining and alcian blue 
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staining were performed with histological sections of femurs or clavicle bones using standard protocols. 
For all skeletal analyses, at least 3 litters for each embryonic stage and at least 5 embryos for each 
genotype were examined. Bone histomorphometry analyses were performed on L3 and L4 vertebrae 
as described previously (Chappard et al., 1987; Parfitt et al., 1987b). Von Kossa/van Gieson Staining, 
toluidine blue staining and calcein double-labeling were performed to measure mineralized bone 
volume over the total tissue volume (BV/TV), osteoblast number per tissue area, (N.Ob/T.Ar), 
mineralization apposition rate (MAR) and bone formation rate per bone surface  (BFR/BS). For in situ 
hybridization, tissues were fixed in 4% paraformaldehyde/PBS overnight at 4°C and then after serial of 
dehydrations embedded in paraffin and sectioned at 5μm. In situ hybridization was performed using 
35
S-labeled riboprobe as described (Ducy et al., 1997). The Runx1, Runx3, Runx2, α1(I)Col, α1(II)Col, 
α1(X)Col, Osteocalcin and Bsp probes have been previously described (Takeda et al., 2001b).  
 The Glut1 probe is a 500-bp fragment of the Glut1 3′ untranslated region (its sequence is described 
below). Hybridizations were performed overnight at 55°C, and washes were performed at 63°C.   
 












µCT analysis  
Trabecular and cortical bone architecture of proximal femur was assessed using a µCT system 
(VivaCT 40; SCANCO Medical AG). Trabecular bone volume, number of trabeculae, cortical bone 
midshaft thickness and mineralization density were analyzed using the standard software provided by 
the manufacturer of the µCT scanner. 
 
Metabolic tests 
All experimental mice were performed on 3-month old male mice fed a regular diet (PicoLab 
Rodent Diet 20 #5053). Glucose stimulated insulin secretion test (GSIS), glucose tolerance test (GTT) 
and insulin tolerance test (ITT) were performed as described previously (Lee et al., 2007).  
 
Serum biochemistry  
ELISAs were used to measure mouse insulin (Ultra Sensitive Mouse Insulin ELISA, Crystalchem), 
mouse PINP (Rat/mouse PINP EIA, IDS) and total and undercarboxylated forms of mouse osteocalcin 
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(Ferron et al., 2010m). Both osteocalcin and PINP were measured at random fed state in all mice 
analyzed. 
 
BrdU incorporation assay 
BrdU saline solution was IP injected in P14 mice at dose of 100g/g 16hrs before sacrifice. Calvaria 
bones were dissected and fixed in 4%PFA overnight at 4°C, decalcified in 14% EDTA for 3 days, 
soaked in 30% sucrose in PBS for 1 day, embedded in O.C.T. compound (Tissue-Tek) and sectioned at 
5m. BrdU incorporation was detected by using BrdU detection Kit (Roche). Immunohistofluorescence 
staining using anti-RUNX2 (Santa Cruz Biotech) was performed with standard protocol in the same 
section to label osteoblasts. Proliferating osteoblasts were identified as both BrdU and RUNX2 positive 
cells and quantified using Image J software. 
 
Measurement of adenosine levels  
Osteoblasts were homogenized and incubated immediately in 10 volumes boiled Tris-Acetate buffer 
(0.1M Tris, 2mM EDTA pH7.8) for 90 seconds to extract adenosine. Levels of ATP, ATP+ADP and 
ADP+AMP were measured in the total cell lyses using a luciferase-based assay (AMP-Glo™ Assay, 
Promega). Cellular contents of ATP, ADP and AMP were calculated accordingly and normalized to 




mTOR kinase assay 
Glut1fl/fl and Glut1-/- Osteoblasts were incubated in differentiation medium for 7 days. Five hundred 
micrograms of total protein lyses were used for immunoprecipitation assay according to a standard 
protocol (Cell Signaling Technology, Inc.). Activity of mTORC1 complex was assessed by 
immunoprecipitation of mTOR using anti-mTOR antibody (Emdmillipore), followed by kinase assay 
using K-LISA™ mTOR Activity Kit (Emdmillipore).  
 
Measurement of collagen synthesis rate  
Collagen synthesis rate was determined by 
3
H-proline incorporation assay as described previously 
(Webster and Harvey, 1979). Briefly, osteoblasts were cultured in medium containing 2μCi of 
3
H-labeled-proline (PerkinElmer) for 24hrs. Collagens were extracted by pepsin/acetic acid solution 
followed by salt precipitation. Incorporation of 
3
H-proline (Perkin Elmer, NET483001MC) in collagen 
molecules was measured by liquid scintillation counter (WALLAC 1409) and normalized to DNA 
content (DNA quantitation kit, Sigma).  
 
Detection of ubiquitination  
Osteoblasts were incubated in medium containing 25nM bortezomib for 16 hrs. Five hundred 
micrograms of total protein lyses were used for immunoprecipitation assay according to a standard 
protocol (Cell Signaling Technology, Inc.). Ubiquitination of RUNX2 was assessed by 
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immunoprecipitation of the RUNX2 using anti-RUNX2 antibody (Santa Cruz), followed by 
immunoblotting using anti-Ubiquitin antibody (Cell Signaling Technology, Inc.).  
 
In vitro AMPK phosphorylation assay 
GST-SMURF1 and GST-RUNX2 constructs were generated by subcloning mouse Smurf1 and Runx2 
cDNAs into pGEX4T3. GST-Smurf1 S148A construct was then generated by mutating serine 148 
(TCA) to alanine (GCA) using standard site directed PCR mutagenesis protocol. GST-SMURF1, 
GST-SMURF1 S148A and GST-RUNX2 were expressed in Rosetta 2 (DE3)pLysS (Novagen) and 
purified as previously described (Ferron et al., 2010a). To assess AMPK phosphorylation of SMURF1, 
10μg of purified GST-SMURF1 was incubated with 10ng AMPK (A1/B1/G1) (Promega) for 30min at 
30˚C in kinase assay buffer containing 5mM MOPS, pH7.2, 2.5mM glycerol 2-phospate, 5mM MgCl2, 
1mM EGTA, 0.4mM EDTA, 0.05mM DTT, 50μM ATP, 5Ci [γ
32
 P] ATP and 0.1mM AMP. The reaction 
was stopped by the addition of Laemmli buffer, and proteins were resolved on SDS-PAGE gel. 
Phosphorylation of SMURF1 was detected by exposing the gel to a radiographic film. In the 
phosphorylation reactions used for mass spectrometry analysis, nonradioactive ATP was used. 
 
LC-MS/MS 
A coomassie-stained band corresponding to SMURF1 phosphorylated by AMPK was excised from a 
SDS-polyacrylamide gel, and subjected to LC-MS/MS at W. M. Keck Foundation Biotechnology 





In vitro ubiquitination assay. 
In vitro ubiquitination of RUNX2 by Smuf1 was assessed as previously described (Lu et al., 2008) 
using 10μg of purified GST-RUNX2 and 0.7μg of GST-SMURF1 WT or GST-SMURF1 S148A. 
Phosphorylated form of GST-SMURF1 was obtained by conducting AMPK phosphorylation assay 
described above. Samples were incubated with 0.7μg of E1, 1μg of UbcH5c (E2), 15μg of ubiquitin 
(Boston Biochem) in ubiquitination assay buffer
 
(50mM Tris-HCl pH 8.0, 50mM NaCl, 1mM dithiothreitol, 
5mM MgCl2, 3mM ATP) for 15min at 30˚C and the reaction was terminated by the addition of Laemmli 
buffer before Western blotting with an anti-Ubiquitin antibody.  
 
Streptozotocin treatment 
Streptozotocin (Sigma) solution (5, 10 or 15mg/ml) was freshly prepared in 50mM citrate buffer (pH4.5). 
At E0.5, pregnant female mice following 6-hour fast received one IP injection of STZ at a dose of 50, 
100 or 150mg/kg. Random feed glucose levels were monitored multiple time points during pregnancy 
and at the time of sacrifice to confirm development of hyperglycemia. Serum insulin levels of the 
pregnant females were measured at E18.5.  
 
Immunohisochemistry 
Immunohisochemistry of paraffin sections of bones of E18.5 embryos was carried out using rabbit 
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anti-type I Collagen (Rockland Immunochemicals Inc.), anti-type X Collagen (Thermo Fisher Scientific 
Inc.) and HRP-goat anti-Rabbit IgG Tyramide Signal Amplification kit (Life technologies) according to 
manufacture’s protocol. Briefly, following deparaffinization and rehydration, 5µm paraffin sections of 
bones were subjected to Pepsin digestion (4mg/ml) at 37°C for 10 min and then incubated with a 1:200 
dilution of primary antibody overnight at 4°C. The next day, following three times washing with 1XPBS, 
sections were incubated with a 1:100 dilution of anti- Rabbit-HRP conjugate secondary antibody for 1 
hour at RT. Next, sections were rinsed three times with 1XPBS and then incubated with 100L Alexa 
Fluor® 568 dye tyramide solution for 10 minutes at RT. After rinsed three times with 1XPBS, sections 
were mounted Fluoro-Gel with DAPI to counterstain nuclei (Electron Microscopy Sciences).    
 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed on lysates from primary osteoblasts with the 
ChIP Assay Kit (Millipore, #17-295) and a ChIP grade anti-RUNX2 antibody (Santa Cruz Biotech). 
Binding of RUNX2 to the -811bp Glut1 promoter region was detected by PCR using following primers: 
forward: 5’ ACCTAGATGGGACATGGACTG 3’ and reverse:  5’ ATCAAACCCTGGGCTATGAGAA 3’. 
Negative control is a region that is at -4286bp of the Glut1 promoter (forward: 5’ 
GGTTTTGGTGGCTTGAGGTA 3’ and reverse: 5’ TGTCTAATGCATATTGGACTTCTGT 3’).   
 
DNA transfection and luciferase assay 
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Mouse Glut1 promoter 1kb fragment was amplified by PCR, sequenced and subcloned upstream of 
the Luciferase gene in the pGL3 Luciferase vector (Promega). Conserved RUNX2 recognition site at 
-811bp “ACCACA” was mutated to “AGAACA” using standard site directed PCR mutagenesis protocol. 
pcDNA-Runx2 and pcDNA-Runx1 were generated previously (Ducy and Karsenty, 1995; Jiang et al., 
2005). These plasmids were then co-transfected into COS-7 cells along with pCMV β-gal control 
plasmid using Lipofectamin 2000 according to manufacturer’s protocol (Invitrogen). Twenty-four hours 
post-transfection, luciferase activity was measured and normalized to beta-galactosidase levels as 
described previously (Ducy and Karsenty, 1995). Relative Luciferase activity was calculated with 
respect to cells transfected with pcDNA3.0 vector.  
 
Statistics 
All data are presented as mean ± standard error of mean. Statistical analyses were performed using 
unpaired, two-tailed Student’s t test for comparison between two groups, ANOVA test for experiments 
involving more than two groups. For all experiments, * denotes P ≤ 0.05, # denotes P≤ 0.001 





Insulin-independent glucose uptake in osteoblasts 
To determine what is/are the main nutrient(s) used by osteoblasts we measured their oxygen 
consumption rate (OCR) when incubated with individual nutrients. Like neurons and unlike myoblasts, 
osteoblasts had the highest OCR when cultured in the presence of glucose and the lowest when 
cultured in the presence of a representative fatty acid (Figure 1A). These results prompted us to 
measure through euglycemic hyperinsulinemic clamps the amount of glucose taken up by bone and 
the mechanism whereby it occurs in 3 month-old wild-type (WT) mice.  
In the conditions of this assay bone takes up a fifth of the quantity of glucose taken up by skeletal 
muscle, the organ taking up the majority of glucose in the mouse (Ferrannini et al., 1988), and half of 
what is taken up by white adipose tissue (WAT) (Figure 1B). Unlike what is the case for skeletal muscle 
and WAT, glucose uptake in bone is not enhanced by insulin (Figure 1B). We also compared the 
uptake of 2-[U-
14
C] deoxyglucose (2-DG) in osteoblasts and osteoclasts, to the one in myoblasts. Both 
bone cell types take up approximately a third of the quantity of 2-DG taken up by myoblasts and do so in 
an insulin-independent manner (Figure 1C). Consistent with these observations, Glut1 that transports 
glucose in an insulin-independent manner, is expressed two orders of magnitude higher than any other 
class I glucose transporters in bone cells (Figure 1D). The rest of this study focuses on the functions of 
glucose in osteoblasts.  
To establish the biological importance of Glut1 expression in these cells, we analyzed osteoblasts 
lacking or over-expressing modestly (1.75 fold) Glut1 (Figure S1A-B). To do so, Glut1fl/fl osteoblasts 
70 
 
were infected with adenovirus expressing either empty vector (GFP) or the Cre recombinase to 
generate control or Glut1 deficient osteoblasts. Glut1-/- osteoblasts took up 75% less and 
α1(I)Col-Glut1 osteoblasts 20% more 2-DG than control osteoblasts (Figure 1E). Consequently, 
glycogen content was decreased 50% in Glut1-/- and increased 40% in α1(I)Col-Glut1 osteoblasts 
compared to control ones (Figure S1C). Thus GLUT1 is responsible for the majority of glucose uptake 
in osteoblasts.  
Glucose uptake is necessary for osteoblast differentiation during development  
Next we analyzed Glut1’s spatial and temporal pattern of expression during skeletogenesis by in situ 
hybridization and compared it to that of α1(I) collagen and Runx2, two marker genes of mesenchymal 
cells and osteoblasts; of α1(II) Collagen, a marker of non–hypertrophic chondrocytes; and of α1(X) 
collagen a marker of hypertrophic chondrocytes. 
At E10.5 Glut1 is highly expressed in α1(I) Collagen-expressing mesenchymal cells of the developing 
hindlimbs (Figure 1F panels a-j). Runx2 begins to be expressed in α1(I) Collagen/Glut1-expressing 
cells at E12.5 and remains expressed in these cells throughout development (Figure1F, panels k-o). 
Prior to E12.5 another Runx gene, Runx1, is expressed in α1(I) Collagen/Glut1-expressing cells 
(Figure1F, panels p-t). The third Runx gene, Runx3 is not expressed before E13.5 and its expression is 
predominant in α1(II) Collagen-expressing chondrocytes (Figure1F, panels u-y, z-b1). Glut1 is virtually 
not expressed in chondrocytes (Figure 1F, panels a-e and z-e1). In view of this pattern of expression, 
we analyzed the function of Glut1 during osteoblast differentiation by crossing mice harboring a floxed 
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allele of Glut1 (Figure S2A) with mice expressing the Cre recombinase under the control of Dermo1 
(Yu et al., 2003) (Glut1dermo1-/-) that delete genes starting at E12.5, or of Osterix regulatory elements 
(Rodda and McMahon, 2006) (Glut1osx-/-) that delete genes starting at E14.5. We verified in each case 
that Glut1 was efficiently deleted in the targeted cells but not in other cell types or tissues and that 
expression of other Gluts was not affected by the Glut1 deletion (Figure S2B-E).  
Using alcian blue/alizarin red staining of skeletal preparations to distinguish non-mineralized (blue) 
from mineralized ECM (red), Glut1dermo1-/- and control embryos were indistinguishable until E13.5 
(Figure S2F). E14.0 was the first time point when a delay in ECM mineralization in long bones and the 
jaws was seen in Glut1dermo1-/- embryos (Figure 2A). This difference in ECM mineralization between 
control and Glut1dermo1-/- embryos was verified histologically (Figure 2B). At E14.5 ECM mineralization 
was still absent in the mandibles of Glut1dermo1-/- embryos (Figure 2A). Beyond E14.5 we also studied 
Glut1osx-/- embryos. At E15.5 large area of mineralized ECM were present in the axial skeleton of 
controls but not of Glut1osx-/- and Glut1dermo1-/- embryos except in long bones (Figure 2C, S2F). Von 
Kossa staining of histological sections detected extensive ECM mineralization in skeletal elements of 
control embryos, while this mineralization was more restricted in Glut1osx-/- embryos; alcian blue 
staining of these sections showed that the ECM in Glut1osx-/- skeletal elements was mostly of 
cartilaginous nature (Figure 2D). Consistent with this observation, α1(X) Collagen-expressing 
hypertrophic chondrocytes covered a larger area in Glut1osx-/- than in control skeletal elements and 
expression of Osteocalcin, was undetectable in Glut1osx-/- skeletal elements (Figure 2E) indicating that 
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osteoblast differentiation was delayed in E15.5 Glut1osx-/- embryos. Remarkably, despite these delays 
in osteoblast differentiation and bone formation, Runx2 and α1(I) Collagen were normally expressed in 
E15.5 Glut1osx-/- skeletal elements (Figure 2E).  
At E18.5, the skull of Glut1osx-/- embryos that ossifies mostly through an intramembranous process 
was poorly mineralized suggesting that osteoblast differentiation was delayed (Figure 2F). Von Kossa 
staining of histological sections showed numerous, long, and thick trabeculae in controls but not in 
Glut1osx-/- long bones and an alcian blue staining showed many more cartilaginous remnants in 
Glut1osx-/- than in control skeletal elements (Figure 2G). Accordingly, the area occupied by α1(X) 
Collagen-expressing hypertrophic chondrocytes remained larger in Glut1osx-/- than in control skeletal 
elements and expression of Osteocalcin was still barely detectable (Figure 2H-J). This incomplete 
osteoblast differentiation in Glut1osx-/- bones and osteoblasts was further illustrated by the decreased 
expression of Bsp (Figure 2I-J). This delay in osteoblast differentiation explains why E18.5 Glut1osx-/- 
embryos had open fontanelles and hypoplastic clavicles (Figure 2F). Even though these two features 
are characteristic of CCD, a disease caused by a decrease in the function of RUNX2 (Lee et al., 
1997a; Mundlos et al., 1997a), Runx2 expression was normal in E18.5 Glut1osx-/- bones. The same 
was true for α1(I) Collagen expression (Figure 2H-J). 
Accounting for this delay in osteoblast differentiation and CCD phenotype, there was a 70% decrease 
in RUNX2 accumulation in E18.5 Glut1osx-/- bones and Glut1-/- osteoblasts that were generated by 
infecting Glut1fl/fl osteoblasts with adenovirus expressing Cre recombinase (Figure 2K). This decrease 
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in RUNX2 accumulation was not observed for other transcription factors (Figure S2G). There was also 
a 70% decrease in Type I collagen accumulation in E18.5 Glut1-/- bones and osteoblasts because of a 
60% decrease in the rate of collagen synthesis in Glut1-/- compared to control osteoblasts (Figure 
2K-L). This latter finding explained the decreased bone formation in Glut1osx-/- embryos. Of note, 
Chrebp, a transcriptional mediator of glucose signaling in other cell types (Yamashita et al., 2001), is 
not expressed and does not regulate glucose uptake in osteoblasts (Figure S2H-K). 
Glucose uptake in osteoblasts is necessary for bone formation and whole-body glucose 
homeostasis post-natally 
To study Glut1 functions in osteoblasts post-natally, we crossed Glut1fl/fl mice with 
Osteocalcin-Cre mice (Glut1ocn-/-) that do not initiate gene deletion before E18.5 (Zhang et al., 2002) 
and performed an inducible deletion of Glut1 in osteoblasts in 6 week-old Osx-Cre;Glut1fl/fl mice 
(Glut1Dox-/-). After verifying the specificity and efficiency of the gene deletions (Figure S3A-B), we 
examined both models of Glut1-/- mice at 3 months of age and included in this analysis α1(I)Col-Glut1 
mice that overexpress modestly (1.75-fold) Glut1 in osteoblasts (Figure S2D).   
Glut1ocn-/- and Glut1Dox-/- mice of either sex presented with a low bone mass in all bones analyzed 
whereas α1(I)Col-Glut1 mice displayed a high bone mass. In these mouse models, only parameters of 
bone formation i.e., circulating levels of PINP, mineral apposition rate, bone formation rate and 
osteoblasts number were affected (Figure 3A-C, S3C-E). Expression of the cell cycle regulators Ccnd2, 
Ccne1 and Cdk4, and osteoblast proliferation as measured by BrdU incorporation were decreased in 
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Glut1ocn-/- and increased in α1(I)Col-Glut1 bones (Figure 3D-E).  Again the accumulation not the 
expression, of RUNX2 and Type I collagen was decreased in Glut1ocn-/- and increased in 
α1(I)Col-Glut1 bones (Figure 3F-G).  
Following the fluctuation of RUNX2 accumulation, expression of Osteocalcin, a RUNX2 
target gene, and circulating osteocalcin levels were low in Glut1ocn-/- mice and high in α1(I)Col-Glut1 
compared to control mice (Figure 3F, S3F). As a result, insulin secretion after glucose stimulation, 
glucose tolerance measured by a glucose tolerance test, insulin sensitivity assessed by an insulin 
tolerance test and the steady-state glucose infusion rate during euglycemic-hyerpinsulinemic clamp, 
were suppressed in Glut1ocn-/- mice and improved in α1(I)Col-Glut1 compared to control mice (Figure 
3H-N).  In summary, glucose uptake in cells of the osteoblast lineage is necessary for osteoblast 
differentiation, bone formation, and whole-body glucose homeostasis.  
Glucose uptake favors osteoblast differentiation and bone formation by inhibiting AMPK  
To determine if the delay in osteoblast differentiation and the decrease in bone formation 
seen in Glut1osx-/- embryos and mice were due to a decrease in protein synthesis that a poor glucose 
uptake triggers (Jeyapalan et al., 2007; Mayer et al., 2011), we measured AMP, ADP and ATP contents 
in Glut1-/- osteoblasts that were generated by infecting Glut1fl/fl osteoblasts with adenovirus 
expressing Cre recombinase.   
Although AMP and ATP levels were not affected, there was a 3-fold increase in ADP content 
leading to a 3-fold increase in the ratio of ADP over ATP in Glut1-/- versus control osteoblasts that were 
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generated by infecting Glut1fl/fl osteoblasts with empty vector (Figure 4A, S4A). As a result, AMPK 
activity assessed by the phosphorylation of its α subunit at Thr172 and of its substrate ACC1 at Ser79 
(Wilson et al., 1996; Woods et al., 1994) was increased (Figure 4B). Several lines of evidence 
indicated that the activity of the mTORC1 complex was decreased in Glut1-/- osteoblasts. 
Phosphorylation of the mTORC1 substrates p70S6K at Thr389, 4E-BP1 at Thr37 and eIF4G at 
Ser1108, was decreased (Bolster et al., 2002; Reiter et al., 2005) (Figure 4C), Raptor phosphorylation 
at Ser792 was increased and mTORC1 kinase activity was decreased in Glut1-/- osteoblasts (Figure 
4B, D). Conversely, p70S6K
 
phosphorylation and collagen accumulation were both decreased in 
Raptor-/- osteoblasts and knockdown of Tsc1 and Tsc2 not only restored mTORC1 activity as 
measured by p70S6K
 
phosphorylation but also normalized collagen accumulation in Glut1-/- 
osteoblasts (Figure 4E, F).  
To demonstrate that the decrease in mTORC1 activity and the phenotypes of the Glut1osx-/- mice are 
caused by an increase in AMPK activity in osteoblasts we decreased the expression of Ampk in 
osteoblasts by generating Glut1-/- embryos or mice lacking in osteoblasts one allele of Ampkα1, the 
most highly expressed AMPK α subunit in these cells (Figure 4G). Phosphorylation of AMPKα1 and 
p70S6K, ATP contents, RUNX2 and Type I collagen accumulations were similar in 
Glut1osx-/-;Ampka1osx+/- and control osteoblasts indicating that AMPK activity and therefore mTORC1 
signaling had been restored in Glut1osx-/-;Ampka1osx+/- osteoblasts (Figure 4H, S4B-C). As a result, 
alcian blue/alizarin red staining of skeletal preparations, histological and in situ hybridization analyses 
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showed normal osteoblast differentiation and no evidence of CCD in Glut1osx-/-;Ampka1osx+/- embryos 
(Figure 4I-L). Bone formation parameters were also normal in Glut1ocn-/-;Ampka1ocn+/- mice (Figure 
4M).  
Two experiments showed that increasing AMPK activity in osteoblasts is deleterious for bone. Treating 
mouse osteoblasts with AICAR, an AMPK agonist, profoundly decreased Type I collagen and RUNX2 
accumulations in these cells and, WT mice treated with AICAR from 6 to 14 weeks of age showed a 
significant decrease in bone formation parameters and bone mass (Figure 4N-O). Accordingly and as it 
is the case for Glut1-/- osteoblasts, WT osteoblasts deprived of glucose had higher levels of P-AMPK 
and lower levels of P-P70S6K and type I collagen than if cultured in the presence of glucose (Figure 
S4D). 
Runx2 cannot induce osteoblast differentiation when glucose uptake is hampered  
In the course of these experiments, we noticed that RUNX2 ubiquitination was increased in 
Glut1-/- osteoblasts generated by infecting Glut1fl/fl osteoblasts with adenovirus expressing Cre 
compared with control osteoblasts generated by infecting with adenoviral empty vector. RUNX2 
accumulation was restored when Glut1-/- osteoblasts were treated with an inhibitor of proteasome 
degradation (Figure 5A). To add credence to this observation we analyzed Glut1-/-;Ampka1+/- and 
Glut1-/-;Ampka1-/- osteoblasts generated by infecting Glut1fl/fl;Ampka1fl/+ and Glut1fl/fl;Ampka1fl/fl, 
osteoblasts with either empty vector or Cre-expressing adenovirus, respectively. RUNX2 ubiquitination 
is normal in Glut1-/-;Ampka1+/- and Glut1-/-;Ampka1-/- osteoblasts (Figure 5B) implicated AMPK in 
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RUNX2 polyubiquitination. Mass spectrometry and bioinformatics analyses identified a possible AMPK 
recognition site in SMURF1, an E3 ubiquitin ligase involved in RUNX2 degradation (Zhao et al., 2003) 
(Figure S5A-B). In vitro, AMPK phosphorylated SMURF1 at Ser148 and this phosphorylation event 
was needed for SMURF1-induced RUNX2 ubiquitination (Figure 5C-D). SMURF1 phosphorylation at 
Ser148 did not increase in Ampka1-/- osteoblasts and RUNX2 accumulation did not decrease in 
Ampka1-/- or Smurf1-/- osteoblasts cultured in the absence of glucose as it did in WT osteoblasts 
(Figure 5E-F). Moreover, an anti-phospho-SMURF1 antibody demonstrated AMPKα1 interaction with 
phospho-SMURF1 in Glut1-/- osteoblasts and that SMURF1 phosphorylation at S148 was higher in 
Glut1-/- than in control, Glut1-/-;Ampka1+/- and Glut1-/-;Ampka1-/- osteoblasts (Figure 5G-H). These 
results indicate that AMPK favors RUNX2 proteasomal degradation by phosphorylating SMURF1.   
This unanticipated regulation of RUNX2 ubiquitination by AMPK allowed assessing selectively the 
ability of RUNX2 to induce osteoblast differentiation when glucose uptake is compromised. This was 
achieved by generating Glut1osx-/- embryos and Glut1ocn-/- mice lacking one allele of Smurf1. This 
manipulation normalized RUNX2 accumulation but did not restore mTORC1 signaling since p70S6K 
phosphorylation and Type I collagen synthesis remained low in Glut1osx-/-;Smurf1+/- osteoblasts 
(Figure 5I-J). As a result and despite a normal accumulation of RUNX2, skeletal development was 
equally delayed in Glut1osx-/-;Smurf1+/- and Glut1osx-/- embryos at E15.5 and E18.5 (Figure 5K-L). The 
cartilaginous area and the zone of α1(X)Col-expressing cells were as enlarged in Glut1osx-/-;Smurf1+/- 
as in Glut1osx-/- embryos (Figure 5M-N). Hence, RUNX2 cannot induce proper osteoblast 
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differentiation during embryogenesis if glucose uptake is hampered because protein synthesis is 
decreased (Figure 5O). Likewise, Glut1ocn-/-;Smurf1+/- mice were as osteopenic as Glut1ocn-/- mice 
(Figure S5C).  
Glucose can initiate bone formation in Runx2-deficient embryos 
We next asked if conversely, raising the extracellular concentration of glucose was sufficient 
to initiate Type I collagen synthesis in Runx2-deficient osteoblasts. To that end Runx2fl/fl osteoblasts 
(Takarada et al., 2013) were infected with a Cre-expressing adenovirus (Figure S6A), these Runx2-/- 
osteoblasts were then cultured in a differentiation medium containing either 5 or 10mM glucose.   
In Runx2-/- osteoblasts cultured in the presence of 5mM glucose, GLUT1 accumulation and glucose 
consumption rate were decreased, phosphorylation of AMPKα1 was high, phosphorylation of p70S6K 
was low indicating that mTORC1 signaling was inhibited. As a result, 
3
H-proline incorporation into 
collagen molecules and accumulation of Type I collagen were lower in Runx2-/- than in control 
osteoblasts (Figure 6A-C). In contrast, when the glucose concentration in the culture medium of 
Runx2-/- cells reached 10mM, the glucose consumption rate doubled, phosphorylation of AMPKα1 and 
p70S6K, incorporation rate of 
3
H-proline into collagen molecules and the accumulation of Type I 
collagen were normalized in Runx2-/- cells, even though Type I Collagen gene expression was not 
changed (Figure 6A-D).  
In view of these results we asked whether a chronic hyperglycemia would improve bone 
formation in Runx2+/- embryos. This was achieved by injecting streptozotocin (STZ, 150mg/kg) in 
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Runx2+/- female mice as soon as a vaginal plug was seen. By decreasing the number of β-cells and 
circulating insulin levels this manipulation caused a severe hyperglycemia in E18.5 embryos (Figure 
6E). We focused our analysis on bones forming through intramembranous ossification because they 
are the ones in which osteoblast differentiation is hampered by Runx2 haplo-insufficiency. While no 
difference was seen in WT embryos carried by STZ-treated mothers (Figure S6B), alcian blue/alizarin 
red staining of skeletal preparations showed that clavicles of E18.5 Runx2+/- embryos carried by 
STZ-treated mothers were twice as long as those of Runx2+/- embryos carried by vehicle-treated 
mothers (1.78±0.08 & 0.85±0.05 mm). Interparietal bones were also two-fold larger in Runx2+/- 
embryos carried by STZ-treated mothers (2.09±0.12 & 1.01±0.13 mm
2
) than in those carried by control 
mothers and fontanelles of these embryos were less open than those of Runx2+/- embryos carried by 
vehicle-treated mothers (Figure 6F-G). Histological analyses showed the presence of mineralized 
bone trabeculae in the clavicles of E18.5 Runx2+/- embryos carried by STZ-treated mothers (Figure 
6H-I). An immunohistochemistry analysis showed the presence of Type I collagen molecules in the 
clavicles of Runx2+/- embryos carried by STZ-treated mothers whereas only Type X collagen 
molecules were present in those of Runx2+/- embryos carried by vehicle-treated mothers (Figure 6J). 
Accumulation of Type I collagen was also increased in long bones of Runx2+/- embryos carried by 
STZ-treated mothers (Figure 6K-L). To further link the rescue of the bone phenotype in Runx2-deficient 
embryos to the increase in blood glucose levels, we repeated this experiment using lower doses of 
STZ (50 or 100mg/kg). One hundred mg/kg of STZ was toxic for β-cells since it decreased circulating 
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insulin levels nearly two-fold without raising blood glucose levels in mothers or embryos (Figure 6E). 
This STZ dose did not correct the delay in bone development of Runx2-deficient embryos (Figure 
6F-G). Thus, raising blood glucose levels normalized collagen synthesis and enhanced bone formation 
in Runx2+/- osteoblasts and embryos.  
Although Type I collagen accumulation was also normalized in skeletal elements obtained 
form Runx2-/- embryos carried by STZ-treated mothers (Figure 6M), alcian blue/alizarin red staining of 
skeletal preparations failed to show any ECM mineralization in the skeleton of E18.5 Runx2-/- embryos 
carried by STZ-treated mothers (Figure S6C). This is probably explained by the fact that RUNX2 
regulates the expression of Alkaline Phosphatase (Akp2), a gene necessary for bone mineralization 
(Murshed et al., 2005) (Figure 6N, D).     
A crosstalk between Runx2 and Glut1 coordinates osteoblast differentiation and bone 
formation  
The results presented above delineated the influence of glucose uptake on osteoblast 
differentiation and bone formation but did not explain how these two events are coordinated in vivo. In 
addressing this question we interpreted the fact that Glut1 expression and glucose uptake were 
decreased in Runx2+/- bones (Figure 7A-B) as suggesting that RUNX2 regulates Glut1 expression. 
Runx1 expression in Glut1/α1(I) Collagen-expressing cells of the limb buds prompted us to test if 
Runx1 could trans-activate the Glut1 promoter. 
The Glut1 promoter of the mouse and other vertebrate species has a canonical Runx binding 
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site at -811bp (Figure 7C). Chromatin immunoprecipitation assays verified that RUNX2 binds to this 
site (Figure 7D) and DNA co-transfection experiments performed in COS cells showed that Runx2 or 
Runx1 expression vectors could increase the activity of a Glut1 promoter-luciferase reporter construct 
(pGlut1-Luc) only if this site was intact (Figure 7E). In agreement with these results, expression of 
Glut1 was decreased in Runx2-/- and increased in Schnurri-3-/- osteoblasts (Shn3-/-) that display an 
increase in RUNX2 activity (Jones et al., 2006) (Figure 7F, S7A). These results explained why glucose 
uptake and mTORC1 activity were decreased in Runx2-/- and increased in Shn3-/- osteoblasts (Figure 
7G, 6B).  
If the feed-forward regulation between GLUT1-dependent glucose uptake and RUNX2 
provides an explanation for the coordination of osteoblast differentiation and bone formation, 
Glut1osx+/-;Runx2+/- embryos should display a delay in osteoblast differentiation similar to that of 
Runx2-/- embryos. Alcian blue/alizarin red staining of skeletal preparations showed that 
Glut1osx+/-;Runx2+/- embryos were  indistinguishable from Runx2-/- embryos up until E16.5 (Figure 
7H, S7B). At E18.5, clavicles were barely detectable and most of the bones forming the skull were 
absent or severely hypoplastic in Glut1osx+/-;Runx2+/- embryos (Figure 7I). Alcian blue staining of 
histological sections of long bones showed an enlargement of the area of hypertrophic chondrocytes 
and a cartilaginous ECM in E18.5 Glut1osx+/-;Runx2+/- embryos (Figure 7J). Osteocalcin expression 
was undetectable in E18.5 Glut1osx+/-;Runx2+/- skeletal elements, while it was present in single 
heterozygous embryos. Conversely, the area covered by α1(X)Collagen-expressing cells was greatly 
82 
 
enlarged in E18.5 Glut1osx+/-;Runx2+/- embryos (Figure 7K). The extent of the delay in osteoblast 
differentiation in Glut1osx+/-;Runx2+/- embryos and mice explained why they all died peri-natally. This 
cross-regulation between Runx2 and Glut1 also determined the extent of bone formation since 
3-month-old Glut1ocn+/-;Runx2+/- mice had a low bone mass not seen either in Glut1ocn+/- or Runx2+/- 
mice (Figure 7L).  
Accounting for this severe phenotype and in agreement with the feed forward loop between glucose 
uptake in osteoblasts and RUNX2, the accumulation of GLUT1, Type I collagen and RUNX2 was 
decreased more than 80% and phosphorylation of AMPK and SMURF1 was increased in 
Glut1osx+/-;Runx2+/- compared to single heterozygous bones (Figure 7M). Hence, the cross-regulation 
of RUNX2 and Glut1 is an amplification mechanism that determines the onset of osteoblast 
differentiation and the extent of bone formation throughout life. We also treated Runx2+/- mothers as 
soon as a vaginal plug was observed with STZ (150mg/kg). This dose of STZ raised blood glucose 
levels in mothers and embryos (Figure S7C), and increased bone formation in skeletal elements of the 





This study identifies glucose uptake in prospective osteoblasts as the earliest determinant of 
osteoblast differentiation and bone formation. It also shows that the coordination of osteoblast 
differentiation and bone formation throughout life is maintained by a feed-forward regulation between 
glucose uptake in osteoblasts and RUNX2 accumulation. In addition, glucose uptake in osteoblasts is 
necessary for whole-body glucose homeostasis.   
 
The bases of the coordination between osteoblast differentiation and bone formation  
A striking feature of bone biology that has never been explained is that the synthesis of the main 
constituent of the bone ECM, Type I collagen, precedes the expression of and is not regulated by 
RUNX2, the earliest transcriptional determinant of osteoblast differentiation. This apparent disconnect 
between osteoblast differentiation and Type I collagen synthesis in the bone could be explained by a 
single mechanism controlling both aspects of osteoblast biology and acting upstream of RUNX2. Our 
results suggest that this is the case and that this mechanism is glucose uptake in osteoblast progenitor 
cells. Glucose is the main nutrient of osteoblasts and is taken up by these cells in an 
insulin-independent manner through Glut1 whose expression precedes the one of Runx2. Glucose 
uptake in osteoblasts favors osteoblast differentiation and bone formation through two distinct 
mechanisms. First, by inhibiting the activity of AMPK, glucose uptake enhances the activity of the 
mTORC1 pathway and therefore protein synthesis. Second and unexpectedly, glucose uptake inhibits 
another function of AMPK documented here, its ability to favor RUNX2 ubiquitination in part via 
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SMURF1. The two distinct functions of AMPK in osteoblasts revealed here explain why agonists of 
AMPK activity exert a deleterious influence on bone formation in vivo. 
The Glut1-Runx2 pathway described here could have clinical relevance. For instance, Glut1osx-/- 
embryos develop a CCD, a disease most often caused by a decrease in RUNX2 expression. However, 
a significant number of CCD patients do not have any detectable mutations in Runx2 (Puppin et al., 
2005; Tessa et al., 2003). Conceivably in some of these patients, CCD may be caused by a decrease 
in glucose uptake or utilization in osteoblasts. If this was the case this would further support the notion 
that skeletal dysplasia may have a nutritional basis (Elefteriou et al., 2006). Moreover, the predilection 
of osteoblasts for glucose demonstrated here provides a plausible explanation for why children fed 
chronically a ketogenic diet experience poor longitudinal growth (Groesbeck et al., 2006).  
  
The respective functions of glucose uptake and Runx2 in osteoblasts 
Remarkably, restoring RUNX2 accumulation in Glut1-/- cells did not translate into efficient bone 
formation in vivo simply because in osteoblasts unable to properly take up glucose, protein synthesis 
remains low regardless of the level of expression of Runx2. On the other hand, raising the extracellular 
concentration of glucose was sufficient to initiate bone formation even though osteoblasts were not 
fully differentiated in Runx2+/- embryos. Raising blood glucose levels in Runx2-/- embryos also 
increased collagen synthesis but that did not translate into the presence of a mineralized bone ECM 
because expression of Akp2, a gene necessary for bone ECM mineralization, is low in the absence of 
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Runx2. Thus RUNX2 is necessary for osteoblast differentiation and for bone ECM mineralization but, 
paradoxically, not for the synthesis of the main constituent of this ECM. In broader terms, the 
importance of glucose uptake in osteoblast differentiation described here raises the hypothesis that 
glucose uptake may be a more general determinant of cell differentiation during embryonic 
development. This may be particularly relevant for tissue like muscle that uptakes large amount of 
glucose.  
Independently of its regulation of bone formation, glucose uptake in osteoblasts is necessary for 
another cardinal function of bone: the regulation of whole-body glucose metabolism. Indeed, through 
its regulation of RUNX2 accumulation, glucose favors expression of the hormone osteocalcin. 
 
The synergistic functions of glucose uptake and Runx2 in osteoblasts 
How are osteoblast differentiation and bone formation coordinated throughout life? The fact that 
Runx2-/- and Glut1-/- osteoblasts had a similar metabolic profile suggested that this coordination might 
be explained if Glut1 was a target gene of RUNX2.  
In support of this hypothesis, both molecular and genetic evidences identify RUNX2 as a major 
regulator of Glut1 expression and glucose uptake in osteoblasts. As a result, Runx2-/- osteoblasts bear 
metabolic similarities with Glut1-/- osteoblasts, Glut1osx+/-;Runx2+/- embryos are similar to Runx2-/- 
embryos and Glut1ocn+/-;Runx2+/- mice display an osteopenia not seen in either Runx2+/- or 
Glut1ocn+/- mice. Hence, the reciprocal regulation between GLUT1-mediated glucose uptake and 
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RUNX2 acts as an amplification chamber that determines the onset of osteoblast differentiation and 
the extent of bone formation throughout life. In addition, Runx1 expression in the developing skeleton 
suggests that this Runx protein may regulate Glut1 expression and thereby favors Type I collagen 
accumulation in prospective osteoblasts before E12.5. 
In broader terms, results of this study cannot be separated from the recently described role of 
osteoblasts in maintaining glucose homeostasis in physiological and pathological situations (Ferron et 
al., 2010a; Lee et al., 2007; Wei et al., 2014e). The absolute necessity of glucose uptake for osteoblast 
differentiation, bone formation and glucose homeostasis documented here illustrates from the 
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Figure 1. Insulin-independent glucose uptake in osteoblasts 
A. Oxygen consumption rate (OCR) of osteoblasts, C2C12 myoblasts or hippocampal neurons 
incubated with vehicle, 10mM glucose, 2mM glutamine or 300M palmitate in 1X KHB buffer for 2hrs 
(n=8).  
B. Glucose uptake measured by euglycemic hyperinsulinemic clamps in femurs, white adipose tissue 
and gastrocnemius muscle of WT mice before or after insulin infusion (2.5 mU/kg/min) (n=4);  
C. Uptake rate of 2-DG in osteoblasts (Osb), osteoclasts (Ocl) and myoblasts (n=3).  
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D. Expression of class I Gluts in osteoblasts and osteoclasts assayed by qPCR.  
E. Uptake rate of 2-DG in Glut1fl/fl, Glut1-/-, WT and α1(I)Col-Glut1 osteoblasts (n=6-8). 
F. In situ hybridization analysis of Glut1 (a-e), α1(I) Collagen (f-j), Runx2 (k-o) Runx1(p-t), Runx3 (u-v), 
α1(II) Collagen (z-b1) andα1(X) Collagen (c1-e1) in hind-limbs during embryonic development.  
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure 2. Glucose uptake is necessary for osteoblast differentiation during development  
A. Alcian blue/alizarin red staining of skeletal preparations of E14.0 and 14.5 Glut1dermo1-/- and 
Glut1fl/fl embryos.  
B. Von Kossa staining of skull sections of E14.5 Glut1dermo1-/- and Glut1fl/fl embryos.  




D. Von Kossa or alcian blue staining of femur from E15.5 Glut1osx-/-, Glut1fl/fl and Osx-cre embryos. 
E. In situ hybridization analysis of Osteocalcin, α1(I), α1(X) Collagen and Runx2 expression in E15.5 
Glut1osx-/- and Glut1fl/fl femurs. 
F. Alcian blue/alizarin red staining of skeletal preparations of E18.5 Glut1osx-/-, Glut1fl/fl and Osx-cre 
embryos.  
G. Von Kossa or alcian blue staining of femur from E18.5 Glut1osx-/-, Glut1fl/fl and Osx-cre embryos. 
H. In situ hybridization analysis of Osteocalcin, α1(I), α1(X) Collagen and Runx2 expression in E18.5 
Glut1osx-/- and Glut1fl/fl femurs. 
I. Expression of osteoblast markers in E18.5 Glut1osx-/- and Glut1fl/fl femurs (n=9). 
J. Expression of osteoblast marker genes in Glut1fl/fl and Glut1-/- osteoblasts. (n=6) 
K. α1(I) Collagen and RUNX2 accumulations in E18.5 Glut1osx-/- and Glut1fl/fl femurs and Glut1fl/fl and 
Glut1-/- osteoblasts.  
L. 
3
H-proline incorporation in collagen in Glut1fl/fl and Glut1-/- osteoblasts (n=6). 
All error bars represent standard error of the mean.
 ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure 3.  Glucose uptake in osteoblasts is necessary for bone formation and glucose 
homeostasis post-natally 
A and B. Histomorphometric analysis of L4 vertebrae of 3 month-old Glut1fl/fl, Glut1ocn-/-, WT and 
α1(I)Col-Glut1 male mice (n=9-11). 
C. CT analysis of proximal femurs of Glut1fl/fl and Glut1ocn-/- male mice (n=7).  
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D. Expression of Ccnd2, Ccne1 and Cdk4 in femurs of 3 month-old Glut1fl/fl, Glut1ocn-/-, WT and 
α1(I)Col-Glut1 mice (n=6). 
E. BrdU incorporation in calvaria of P14 Glut1fl/fl, Glut1ocn-/-, WT and α1(I)Col-Glut1 mice (n=5-8). 
F. Expression of osteoblast marker genes in femurs of 3 month-old Glut1fl/fl, Glut1ocn-/-, WT and 
α1(I)Col-Glut1 mice (n=8). 
G. α1(I) Collagen and RUNX2 accumulations in femurs of 3 month-old Glut1fl/fl, Glut1ocn-/-, WT and 
α1(I)Col-Glut1 mice.  
H-I.  GSIS in 3 month-old Glut1fl/fl, Glut1ocn-/-, WT and α1(I)Col-Glut1 mice (n=10-11). 
J-K.  GTT in 3 month-old Glut1fl/fl, Glut1ocn-/-, WT and α1(I)Col-Glut1 mice (n=5-10). 
L. ITT in 3 month-old Glut1fl/fl and Glut1ocn-/-, WT mice (n=8-10). 
M.  Glucose infusion rate in 3 month-old Glut1fl/fl and Glut1ocn-/- mice (n=6).  
N. ITT in 3 month-old WT and α1(I)Col-Glut1 mice (n=8-10). 
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure 4. Glucose uptake favors osteoblast differentiation and bone formation by inhibiting 
AMPK  
A. ADP content and ADP/ATP ratio in WT and Glut1-/- osteoblasts (n=6).  
B-C. AMPK, ACC1, Raptor (B), p70S6K, 4E-BP1 and eIF4G phosphorylation in WT and Glut1-/- 
osteoblasts.   
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D. Kinase assay of immune-precipitated mTORC1 complex in WT and Glut1-/- osteoblasts (n=3).  
E. Raptor, p70S6K phosphorylation and α1(I)Collagen accumulations in WT and Raptor-/- 
osteoblasts.  
F. TSC1, TSC2, and p70S6K phosphorylation, α1(I)Collagen and RUNX2 accumulations in WT and 
Glut1-/- osteoblasts transfected with SiRNAs targeting Tsc1 and Tsc2 or scrambled SiRNA.   
G. Expression of various AMPK subunits in osteoblasts.  
H. AMPK and p70S6K phosphorylation, RUNX2 and α1(I)Collagen accumulations in Glut1fl/fl, 
Glut1osx-/- and Glut1osx-/-;Ampka1osx+/- osteoblasts.  
I-J. Alcian blue/alizarin red staining of skeletal preparations of E15.5 (I) and 18.5 (J) Glut1fl/fl, 
Glut1osx-/-, Ampka1osx+/- and Glut1osx-/-;Ampka1osx+/- embryos. 
K. Alcian blue staining of histological sections of femurs of E18.5 Glut1fl/fl, Glut1osx-/-, Ampka1osx+/- 
and Glut1osx-/-;Ampka1osx+/- embryos. 
L. In situ hybridization analysis of Osteocalcin, α1(I), α1(II) and α1(X) Collagen expression in femurs 
of E18.5 Glut1fl/fl, Glut1osx-/-, Ampka1osx+/-  and Glut1osx-/-;Ampka1 osx+/- embryos. 
M. Histomorphometric analysis of L4 vertebrae of 3 month-old of Glut1fl/fl, Glut1ocn-/-, Ampka1ocn+/- 
and Glut1ocn-/-;Ampka1ocn+/- male mice (n=7-10).  
N. AMPK phosphorylation, RUNX2 and α1(I)Collagen accumulations in osteoblasts treated with 
vehicle or AICAR (0.1mM) for 16 hrs.  
O. Histomorphometric analysis of L4 vertebrae of 3 month-old of WT mice treated with vehicle or 
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AICAR (250mg/kg/day) for 8 weeks (n=6).  
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure 5. Runx2 cannot induce proper osteoblast differentiation if glucose uptake is hampered  
A. Ubiquitination of immune-precipitated RUNX2 in WT and Glut1-/- osteoblasts treated with 25nM 
Bortezomib for 16hrs. 
B. Ubiquitination of immune-precipitated RUNX2 in WT, Glut1-/-, Glut1-/- Ampka1+/- and Glut1-/- 
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Ampka1-/- osteoblasts treated with 25nM Bortezomib for 16hrs. 
C. In vitro AMPK phosphorylation assay of SMURF1 and SMURF1-S148/A. 
D. In vitro ubiquitination assay of SMURF1 and SMURF1-S148/A phosphorylated by AMPK.  
E-F. RUNX2 and α1(I)Collagen accumulations, AMPK and SMURF1 phosphorylation in WT, Smurf1-/- 
(E) and Ampka1-/- (F) osteoblasts cultured with or without glucose for 16 hrs.  
G. Co-immunoprecipitation of AMPKα1 and SMURF1 in WT and Glut1-/- osteoblasts.  
H. RUNX2 and α1(I)Collagen accumulations, AMPKα1, p70S6K and SMURF1 phosphorylation in WT, 
Glut1-/-, Glut1-/- Ampka1+/- and Glut1-/- Ampka1-/- osteoblasts. 




H-proline incorporation in collagen molecules in Glut1fl/fl, Glut1-/- and Glut1-/-;Smurf1+/- 
osteoblasts (n=6). 
K-L. Alcian blue/alizarin red staining of skeletal preparations of E15.5 (G) and 18.5 (I) Glut1fl/fl, 
Smurf1+/-, Glut1osx-/- and Glut1osx-/-;Smurf1+/- embryos. 
M. Alcian blue staining of sections of femurs of E18.5 Glut1fl/fl, Glut1osx-/- and Glut1osx -/-;Smurf1+/-  
embryos. 
N. In situ hybridization analysis of Osteocalcin, α1(I) and α1(X) Collagens expression, in femurs of 
E18.5 Glut1fl/fl, Glut1osx-/- and Glut1osx-/-;Smurf1+/- embryos. 
O. Schematic representation of the pathways triggered by glucose uptake in osteoblasts. 
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All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure 6.  Glucose can initiate bone formation in Runx2-deficient embryos 
A. Glucose consumption rate in WT and Runx2-/- osteoblasts cultured with 5 or 10mM glucose for 
16hrs. 
B. RUNX2, α1(I)Collagen and GLUT1 accumulations, AMPKα1 and p70S6K phosphorylation in WT 
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and Runx2-/- osteoblasts cultured with 5 or 10mM glucose for 14 days. 
C. 
3
H-proline incorporation in collagen molecules in WT and Runx2-/- osteoblasts cultured with 5 or 
10mM glucose for 14 days (n=5). 
D. qPCR analysis of osteoblast marker genes in WT and Runx2-/- osteoblasts cultured with 5 or 10mM 
glucose for 14 days (n=6). 
E. Blood glucose and insulin levels in STZ (50, 100, 150mg/kg) and vehicle-treated Runx2+/- mothers 
and progenies at E18.5 (n=5-12).  
F-G. Alcian blue/alizarin red staining of the skull (F), clavicles and interparietal bones (G) of E18.5 
Runx2+/- embryos carried by STZ (50, 100, or 150mg/kg) and vehicle-treated mothers. 
H-I. Von Kossa/van Gieson staining (H) and H&E staining (I) of clavicles of E18.5 Runx2+/- embryos 
carried by STZ- (150mg/kg) or vehicle-treated mothers. 
J. Immunohistochemical detection of Type I and type X collagens in clavicles of E18.5 Runx2+/- 
embryos carried by STZ- (150mg/kg) or vehicle-treated mothers. 
K. RUNX2 and α1(I)Collagen accumulations in femurs of E18.5 WT and Runx2+/- embryos carried by 
STZ- (150mg/kg) or vehicle-treated mothers. 
L. α1(I) and α2(I) Collagen expression in femurs of E18.5 WT and Runx2+/- embryos carried by STZ- 
(150mg/kg) or vehicle-treated mothers (n=8). 
M. RUNX2 and α1(I)Collagen accumulations in femurs of E18.5 WT and Runx2-/- embryos carried by 
STZ- (150mg/kg)  or vehicle-treated mothers. 
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N. Akp2 expression in femurs of E18.5 of WT and Runx2-/- embryos carried by STZ- (150mg/kg) or 
vehicle-treated mothers (n=6).  
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure 7.  The reciprocal regulation between Runx2 and Glut1 determines osteoblast 
differentiation and bone formation  
A. Glut1 expression in femurs of 3 month-old Runx2+/- mice (n=8).  
B. Uptake rate of 2-DG in the calvaria of 6 week-old WT and Runx2+/- (n=4-5) mice. 
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C. Runx binding sites in the Glut1 promoter of several species. 
D. ChIP assay of RUNX2 binding to the promoter of mouse Glut1.  
E. Luciferase assay of pGlut1-WT-Luc or pGlut1-mut-Luc in COS cells co-transfected with RUNX2 or 
Runx1 expression vector (n=6).  
F. Expression of osteoblast marker genes in WT, Runx2-/- and Shn3-/- osteoblasts (n=6).  
G. Glucose uptake in WT, Runx2-/- and Shn3-/- osteoblasts measured by the uptake rate of 2-DG 
(n=6). 
H-I. Alcian blue/alizarin red staining of skeletal preparations of E16.5 (H) and 18.5 (I) Glut1osx+/-, 
Runx2+/-, Glut1osx+/-;Runx2+/- and Runx2-/- embryos. 
J. Alcian blue staining of histological sections of femurs of E18.5 Glut1osx+/-, Runx2+/-, 
Glut1osx+/-;Runx2+/- and Runx2-/- embryos. 
K. In situ hybridization analysis of Osteocalcin, Bsp and α1(X) Collagen expression, in E18.5 
Glut1osx+/-, Runx2+/- and Glut1osx+/-;Runx2+/- femurs. 
L. Bone histomorphometric analysis of L4 vertebrae of 3 month-old of Glut1fl/+, Glut1ocn+/-, Runx2+/- 
and Glut1ocn+/-;Runx2+/- female mice (n=9-12). 
M. RUNX2 and α1(I)Collagen accumulations and AMPKα1 and SMURF1 phosphorylation in femurs of 
E18.5 Glut1fl/+, Glut1osx+/-, Runx2+/-, and Glut1osx+/-; Runx2+/- embryos. 
N. Alcian blue/alizarin red staining of skeletal preparations of E18.5 Glut1osx+/-;Runx2+/- embryos 
carried by mothers treated with STZ (150mg/kg) or vehicle. 
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All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 






Figure S1. Insulin-independent glucose uptake in osteoblasts (related to Figure 1) 
A. Glut1 expression (qPCR) in Glut1fl/fl (n=7), Glut1-/- (n=9), WT (n=8) and α1(I)Col-Glut1 (n=6) 
osteoblasts.  
B. Western blot of Glut1 in Glut1-/- and α1(I)Col-Glut1 osteoblasts. 
C. Glycogen content in Glut1fl/fl (n=6), Glut1-/- (n=6) WT (n=6) and α1(I)Col-Glut1 osteoblasts (n=6). 
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure S2. Glucose uptake is necessary for osteoblast differentiation during development 
(related to Figure 2) 
A. Targeting strategy used to generate a floxed allele of Glut1 and southern blots on WT and targeted 
ES cell DNA digested with HindIII and NcoI.  
B. PCR analysis of Glut1 deletion allele in various tissues in Glut1demor1-/- and Glut1osx-/- mice.  
C. Western blot analysis of Glut1 accumulation in bones of E18.5 Glut1demor1-/-, Glut1osx-/- and Glut1fl/fl 
embryos. 
D. qPCR analysis of Glut1 expression in osteoblasts (osb), liver, muscle and WAT of Glut1fl/fl (n=6), 
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Glut1osx-/- (n=7), WT (n=7)  and α1(I)Col-Glut1 (n=7) mice.  
E. Expression of Glut2, Glut3 and Glut4 (qPCR) in Glut1fl/fl (n=6) and Glut1osx-/- (n=7) osteoblasts.   
F. Alcian blue/alizarin red staining of skeletal preparations of E13.5, E15.5 and E18.5 Glut1dermo1-/- and 
Glut1fl/fl embryos.  
G. Western blot of ATF4 and c-Myc in Glut1fl/fl and Glut1-/- osteoblasts.  
H. qPCR analysis of Chrebp expression in osteoblasts (Osb), liver, muscle and white adipose tissue 
(WAT).  
I. qPCR analysis of Chrebp and Runx2 expression in osteoblasts. 
J. qPCR analysis of Chrebp expression in osteoblasts treated with or without glucose (n=4 of each 
samples). 
K. qPCR analysis of α1(I)Col1, Runx2, Osterix and Osteocalcin expression in WT and Chrebp-/- 
osteoblasts (n=4 of each genotype). 
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure S3.  Glucose uptake in osteoblasts is necessary for bone formation and glucose 
homeostasis post-natally (related to Figure 3) 
A. PCR analysis of Glut1 deletion allele in various tissues in Glut1ocn-/- mice. 
B. Western blot analysis of Glut1 accumulation in bones of Glut1fl/fl and Glut1ocn-/- mice and Glut1Dox-/- 
mice, in which Glut1 expression was inducibly deleted post-natally. 
C. Bone histomorphometric analysis of L4 vertebrae of 3 month-old Glut1fl/fl females (n=6) and 
Glut1Dox-/- (n=6) fed doxycycline diet (625mg/kg, TD.09651 Harlan) throughout pregnancy until 6 
weeks old, and then fed with normal chow from week 6 to 12 weeks of age to induce Glut1 deletion. 
D. CT analysis of proximal femurs of WT (n=8) and α1(I)Col-Glut1 (n=8) male mice. 
E. Serum levels of PINP of Glut1fl/fl (n=12), Glut1ocn-/- (n=12), WT (n=8) and α1(I)Col-Glut1 mice (n=8) 
mice at 3 month of age. 
F. Serum levels of total and undercarboxylated forms of osteocalcin (Glu13-Ocn) in 3 month-old 
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Glut1fl/fl (n=10), Glut1ocn-/- (n=10), WT (n=8) and α1(I)Col-Glut1 mice (n=8) mice. 
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure S4.  Glucose uptake favors osteoblast differentiation and bone formation by inhibiting 
AMPK (related to Figure 4) 
A. ATP and AMP contents in Glut1fl/fl and Glut1-/- osteoblasts (n=6 of each group).  
B. Quantification of levels of p-AMPK and p-AMPK/AMPK in Glut1fl/fl, Glut1osx-/- and 
Glut1osx-/-;Ampka1osx+/- osteoblasts (n=6).  
C. ATP content in Glut1fl/fl, Glut1-/- and Glut1-/-;Ampka1+/- osteoblasts (n=6 of each group).  
D. α1(I)Collagen accumulation, AMPK and P70S6K phosphorylation in WT, and Glut1-/- osteoblasts 
cultured with or without 5mM glucose for 8 hrs. 
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure S5. Runx2 cannot induce proper osteoblast differentiation if glucose uptake is 
hampered (related to Figure 5) 
A. Putative AMPK phosphorylation site in Smurf1 of various species. 
B. Mass spectrometric analysis of phosphorylation sites in Smurf1 phosphorylated by AMPK in vitro.   
C. Bone histomorphometric analysis of L4 vertebrae of 3 month-old of Glut1fl/fl (n=10), Smurf1+/- 
(n=10), Glut1ocn-/- (n=8) and Glut1ocn-/-;Smurf1+/- (n=9) male mice.  
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure S6.  Glucose can initiate bone formation in Runx2-deficient embryos (related to Figure 
6) 
A. qPCR analysis of Runx2 expression in Runx2-/- osteoblasts (n=6 of each group).  
B. Alcian blue/alizarin red staining of skulls of E18.5 WT embryos carried by STZ (150mg/kg)-treated 
or vehicle-treated mothers. 
C. Alcian blue/alizarin red staining of skeletal preparations of E18.5 Runx2-/- embryos carried by 
STZ(150mg/kg)-treated or vehicle-treated mothers. 
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 





Figure S7.  The reciprocal regulation between Runx2 and Glut1 determines bone formation 
(related to Figure 7) 
A. Western blot analysis of RUNX2 and GLUT1 accumulation in WT and Shn3-/- osteoblasts. 
B. Alcian blue/alizarin red staining of skeletal preparations of E15.5 Glut1osx+/-, Runx2+/-, 
Glut1osx+/-;Runx2+/-, Glut1osx-/- and Runx2-/- embryos. 
C. Blood glucose levels of STZ-treated mother and their E18.5 Glut1osx+/-;Runx2+/- fetus (n=5 of each 
group). 
All error bars represent standard error of the mean. ∗denotes p ≤ 0.05, and # denotes p ≤ 0.001 




CHAPTER III: A single amino acid explains how Smurf1 
regulate osteoblast differentiation, bone formation and 
glucose homeostasis 
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Summary 
 The E3 ubiquitin ligase Smurf1 targets the master regulator of osteoblast differentiation 
Runx2, for degradation yet the function of Smurf1 if any during osteoblast differentiation in vivo is 
ill-defined. Here we show that Smurf1 prevents osteoblast differentiation by decreasing Runx2 
accumulation in osteoblasts. Remarkably, mice harboring a substitution-mutation at serine 148 (S148) 
in Smurf1 that prevents its phosphorylation by AMPK (Smurf1
ki/ki
) display an equally severe premature 
osteoblast differentiation phenotype as Smurf1-/- mice, a high bone mass and are also 
hyperinsulinemic and hypoglycemic. Consistent with the fact that Smurf1 targets the insulin receptor 
for degradation, there is in Smurf1
ki/ki
 mice an increase in insulin signaling in osteoblasts that triggers a 
rise in the circulating levels of osteocalcin, a hormone that favors insulin secretion. These results 
identify Smurf1 as a determinant of osteoblast differentiation during development, of bone formation 
and glucose homeostasis post-natally and demonstrate the necessity of S148 for these functions.  
121 
 
Introduction   
 The transcription factor Runx2 has many attributes of a master regulator of osteoblast 
differentiation. In its absence, there are no osteoblasts anywhere in the skeleton and its 
haplo-insufficiency, by delaying osteoblast differentiation in bone forming through intramembranous 
ossification, results in a cleidocranial dysplasia (CCD), a disease characterized by open fontanelles 
and short clavicles (Ducy et al., 1997; Komori et al., 1997c; Lee et al., 1997d; Mundlos et al., 1997d; 
Otto et al., 1997a). Conversely, an increase in Runx2 activity as seen in mice and humans lacking one 
allele of Twist, results in craniosynostosis because of a premature osteoblast differentiation in the skull 
leading to early closure of the sutures (Bialek et al., 2004).  
Not surprisingly given the paramount importance of this transcription factor for 
skeletogenesis, the mechanisms regulating the accumulation of Runx2 in cells of the osteoblast 
lineage have been intensively studied. Runx2 accumulation in osteoblast progenitor cells and 
differentiated osteoblasts is regulated in part by ubiquitination and several E3 ubiquitin ligases have 
been implicated in targeting Runx2 for degradation (Jones et al., 2006; Kaneki et al., 2006; Zhao et al., 
2003). One of them Smurf1, interacts with Runx2 and other proteins regulating bone mass accrual 
such as Smad1, Smad5, MEKK2 and the insulin receptor (InsR) (Wei et al., 2014a; Yamashita et al., 
2005; Zhu et al., 1999). Consistent with these biochemical findings, forced expression of Smurf1 in 
osteoblasts inhibits, whereas deletion of Smurf1 in all cells favors bone formation in adult mice 
(Yamashita et al., 2005; Zhao et al., 2004). It has been proposed that Smurf1 achieves these functions 
in part by targeting MEKK2 for degradation (Yamashita et al., 2005). Surprisingly given the biochemical 
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evidence indicating that Smurf1 favors the degradation of Runx2, no loss of function study has yet 
addressed the role of Smurf1 as a regulator of osteoblast differentiation in vivo.  
A second important question regarding Smurf1 biology is to identify a domain if not a single 
amino acid that would confer to this protein the ability to target Runx2 for degradation in vivo. This 
question is even more relevant in view of the demonstration that in vitro, Smurf1 must be 
phosphorylated by AMPK on serine 148 (S148) in order to trigger the degradation of Runx2 (Wei et al., 
2015e). This raises the question of the biological importance of this residue in the functions of Smurf1. 
We have addressed the aforementioned questions by analyzing Smurf1-/- mice and mice 
harboring a mutated form of Smurf1 in which S148 is mutated to alanine (Smurf1
ki/ki
). We show here 
that Smurf1 inhibits osteoblast differentiation through its ability to target Runx2 for degradation and that 
this function requires the presence of S148. Remarkably Smurf1
ki/ki
 mice are also hypoglycemic and 
hyperinsulinemic because S148 is needed for Smurf1 ability to target the InsR for degradation. As a 
result, there is an accumulation of the InsR in bones of Smurf1
ki/ki
 mice. This leads to an increase in the 
circulating levels of the bioactive form of the bone-derived hormone osteocalcin that favors insulin 
secretion and can cause hypoglycemia (Ferron et al., 2010a; Lee et al., 2007). These results define 
critical functions of Smurf1 in cells of the osteoblast lineage throughout life and highlight the 









 mice, a mutation was introduced into a BAC by recombineering using galK 
selection system (Warming et al., 2005). In the first step, the galK cassette was inserted into BAC by 
homologous recombination and clones were obtained through positive selection on minimal media 
plates in which galactose was the only carbon source. The successful recombination was validated by 
PCR analysis. In the second step, the galK cassette was substituted by double stranded 
oligonucleotides with the modified base-pair in the middle of the homology arms flanking the galK 
casette. This step was achieved by negatively selecting against the galK cassette by resistance to 
2-deoxy-galactose (DOG) on plates with glycerol as the carbon source. Clones in which galK cassette 
is replaced by a mutation of interest were identified by PCR and sequencing. A frt-neo-frt (FNF) 
cassette was inserted upstream of the mutation and retrieved into pMCS-DTA by homologous 
recombination using standard protocol. The targeting vector that was verified by PCR, diagnostic 
digestions and sequencing, was electroporated into ES cells, positive ES cells were identified by PCR 
screening and sequencing. Selected ES cells were injected in 129Sv/EV blastocysts to generate 
chimeric mice. Chimeric mice were crossed to Gt(ROSA)26Sor
tm1(FLP1)Dym
 to remove the neomycin 
resistance cassette.  
Runx2+/- mice were generated previously (Otto et al., 1997a). Smurf1+/- mice were a generous gift of 
Dr. Jeff Wrana (U of Toronto, Canada) (Narimatsu et al., 2009). All mice strains were maintained on a 
C57/129 mixed background except for Runx2+/- mice, which are maintained on C57 background. 
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Littermates were used as controls in all experiments.  
Cell culture 
Primary mouse calvaria osteoblasts were cultured as described previously (Ducy and Karsenty, 1995). 
To determine formation of mineralized nodule, von Kossa staining was performed on osteoblasts 
cultured in differentiation medium supplemented with 5mM β-glycerophosphate and 100ug/mL 
ascorbic acid for 7 days. To detect the S148 phosphorylation in Smurf1, osteoblasts isolated from 
Smurf1
ki/ki
 and WT pups were incubated overnight in glucose free KRH buffer (50mM HEPES pH7.4, 
136mM NaCl, 4.7mM KCl, 1.25mM MgSO4, 1.25mM CaCl2 and 0.1% BSA) and followed by western 
blot analysis.  
DNA transfection experiments 
Myc-Smurf1 WT and S148A plasmids were constructed by inserting a full-length cDNA of mouse 
Smurf1 WT or S148A into pcDNA
TM
 3.1 /myc-His B vector (Invitrogen). Myc-Smurf1 WT or S148A was 
co-transfected with Flag-Runx2 or the human InsR cDNA expression constructs (Wei et al., 2014a; Wei 
et al., 2015e) in COS-7 cells. DNA transfection experiments were performed using Lipofectamin 2000 
(Invitrogen) according to manufacturer’s protocol.  
Western blot analysis 
Anti-Runx2 antibody (Santa Cruz Biotech Inc.), anti--ACTIN (Sigma), Anti-Smurf1 and 
Anti-Phospho-Ser148 Smurf1 (GenScript Inc.) were used. Others antibodies were obtained from Cell 




Gene expression analysis 
RNA samples were extracted using TRIZOL reagent (Invitrogen). Using two micrograms of total RNA, 
cDNA preparation was carried out following standard protocols. The cDNAs were used as templates 
for quantitative PCR analyses using CFX-Connect realtime PCR system (Bio-Rad). Expression levels 
of each gene analyzed by qPCR were normalized using GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) expression levels as an internal control. The sequences of specific primers used in 
this study were previously described (Obri et al., 2014).  
Skeletal preparation and analysis 
Alcian blue/alizarin red staining of the skeletal preparation was conducted according to standard 
protocols (McLeod, 1980). Littermate controls were analyzed in all experiments. Quantifications of the 
length of clavicles as well as the area of the opening of the skull were made using ImageJ. 
Bone histomorphometry  
This analysis was performed on L3 and L4 vertebrae of 2-month-old female mice as described 
previously (Chappard et al., 1987; Parfitt et al., 1987a). Mineralized bone volume over the total tissue 
volume (BV/TV), osteoblast number per tissue area (N.Ob/T.Ar) as well as trabecular number (Tb.N), 
and bone formation rate per bone surface (BFR/BS) were measured by conducting Von Kossa/ van 
Gieson staining, toluidine blue staining and calcein double-labeling, respectively. Osteoclasts 
parameters were measured by TRAP staining followed by counterstain with hematoxylin. Osteoclasts 
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were defined as multinucleated dark red cells along the bone surface. Histomorphometric analysis was 
performed using the Osteomeasure System (OsteoMetrics).  
Biochemistry 
ELISAs were performed according to manufacturer’s instructions to measure mouse insulin 
(EZRMI-13K, Millipore) and undercarboxylated osteocalcin (Ferron et al., 2010m). For AMPK 
phosphorylation assay, GST-Smurf1 and GST-Runx2 constructs were generated and purified as 
previously described (Ferron et al., 2013; Wei, 2015). AMPK phosphorylation assay of GST-Smurf1 
WT and S148A was performed using previously described method (Wei, 2015).   
GST-Pulldown assay 
GST-Smurf1 WT and GST-Smurf1S148A were bound to glutathione agarose beads (GE Healthcare) 
and blocked overnight at 4˚C in 5%BSA with end-over-end mixing. Beads were washed with AMPK 
assay buffer 5 times and AMPK phosphorylation assay was followed. Beads were washed with binding 
buffer (50mM Tris-Hcl pH 7.5, 100mM NaCl, 50mM β-glycerophosphate, 10% glycerol, 1% Tween-20, 
1mM EDTA, 25mM NaF) 5 times. Cell lysates of transfected COS-7 cells were incubated with 25μg of 
GST for 2 hours at 4˚C with end-over-end mixing. This mixture was centrifuged and supernatants were 
mixed with GST-Smurf1 WT or S148A in 500μL of binding buffer for 2 hours at 4˚C with end-over-end 
mixing. The mixtures were washed 5 times and analyzed by SDS-PAGE followed by immunoblotting.  
In situ hybridization 
Tissues were fixed in 4% paraformaldehyde/PBS overnight at 4°C and then embedded in paraffin after 
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serial of dehydrations. Tissues were sectioned at 5μm. In situ hybridization was performed using 
35
S-labeled riboprobe as described (Ducy et al., 1997). The α1(I)Col, Bsp, and Osteocalcin probes 
were prepared as previously described (Takeda et al., 2001a).  Hybridizations were performed 
overnight at 55°C, and washes were performed at 63°C. Autoradiography were performed as previously 
described (Sundin et al., 1990) and nuclei were counterstained with DAPI.  
Statistics 
All data are presented as mean ± standard error of mean. In this paper, statistical analysis was 







Smurf1 regulates osteoblast differentiation 
 To determine whether Smurf1 affects osteoblast differentiation in vivo, we analyzed in P4 and 
P10 Smurf1-/- mice two parameters that reflect the activity of Runx2 in cells of the osteoblast lineage 
during development: the closure of sutures in the skull and the length of clavicles.  
Alcian blue/alizarin red staining of skeletal preparations showed that clavicles of Smurf1-/- 
mice were significantly longer than those of WT mice (Figure 1A) and sagittal sutures of Smurf1-/- 
skulls showed evidence of craniosynostosis (Figure 1B-C). Next, we analyzed by in situ hybridization 
the expression of Bone sialoprotein (Bsp), a biomarker of osteoblast differentiation (Bialek et al., 2004) 
in calvarial bones of E14.5 WT and Smurf1-/- embryos. The expression of Bsp was stronger in calvarial 
bones of E14.5 Smurf1-/- than in those of WT embryos (Figure 1D). The same was true for the 
expression of Bsp and Osteocalcin (Ocn), another osteoblast differentiation marker, in femurs of E14.5 
Smurf1-/- embryos whether this was assayed by qPCR or in situ hybridization (Figure 1E-G). As a 
negative control in this experiment, we analyzed the expression of α1(I) Collagen (α1(I)Col), that is not 
regulated by Runx2 in vivo (Wei et al., 2015e).  
To link this premature osteoblast differentiation to an increase in Runx2 accumulation, we 
analyzed the abundance of this transcription factor in the skulls of Smurf1-/- and WT littermates and 
observed that Runx2 was more abundant in Smurf1-/- than WT skulls (Figure 1H). This latter result 
explains the increase in the expression of Ocn, a target of Runx2 (Ducy et al., 1997) (Figure 1E, 1G 
and 1I). Taken together, these results established that Smurf1 is a negative regulator of osteoblast 
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differentiation in vivo, and suggested that this function occurs in part by targeting Runx2 for 
degradation. 
 
Serine 148 is necessary for Smurf1 ability to inhibit osteoblast differentiation and bone 
formation 
In vitro the phosphorylation of Smurf1 by AMPK at serine 148 (S148) is needed for its ability 
to target Runx2 for degradation (Wei et al., 2015e). Thus, we tested the importance of this residue for 
Smurf1 ability to inhibit osteoblast differentiation by analyzing mutant mice harboring a S148A mutation 
in Smurf1 (Smurf1
ki/ki
) (Figure S1A-S1C). A western blot analysis verified that the phosphorylation of 
Smurf1 at S148 was abolished in Smurf1
Ki/Ki
 osteoblasts although Smurf1 accumulation was not 
affected (Figure 2A). 
Alcian blue/alizarin red staining of skeletal preparations showed that clavicles were 
significantly longer and sagittal sutures of the skulls more closed in Smurf1
ki/ki
 than in newborn WT 
mice (Figure 2B-D). Accordingly, osteoblasts isolated from Smurf1-/- or Smurf1
ki/ki
 mice formed more 
mineralized nodules than WT osteoblasts (Figure S2A). In vivo, Bsp expression was stronger in 
calvarial bones of E14.5Smurf1
ki/ki
 embryos than in those of WT embryos (Figure 2E). The expression 
of Ocn started earlier and the one of Bsp was stronger in femurs of Smurf1
ki/ki
 than in those of E14.5 
WT embryos indicating that osteoblast differentiation occurred earlier in Smurf1
ki/ki
 embryos throughout 





 embryos was noted (Figure 2F). The expression of Ocn and Bsp was also significantly 
higher in femurs of E14.5 Smurf1
ki/ki
 embryos than in those of WT embryos when measured by qPCR 
(Figure 2G-H).  
That Bsp and Ocn expression was higher in femurs of Smurf1
ki/ki
 mice at P10 (Figure S2B-S2C) 
suggested that this S148A mutation in Smurf1 may affect bone biology post-natally. Indeed, two 
month-old Smurf1
ki/ki
 mice had a higher bone mass and higher trabeculae number than WT littermates 
because of an increase in their osteoblast number and bone formation rate (Figure 2I-L). These 
phenotypes could be traced in part to an increase in the accumulation of Runx2 in Smurf1
ki/ki
 skulls 
(Figure 2M). To ascertain that the phosphorylation of Smurf1 at S148 is needed to target Runx2 for 
degradation, we performed a GST-Pull-down assay and observed that the interaction between Smurf1 
and Runx2 that occurred upon phosphorylation of Smurf1 by AMPK was abrogated when S148 was 
mutated to alanine. Accordingly, forced expression of WT but not S148A Smurf1 decreased the 
accumulation of Runx2 in COS-7 cells (Figure 2N-O). Taken collectively, these data establish the 
importance of S148 for Smurf1 ability to inhibit osteoblast differentiation and bone formation.  
 
Smurf1 inhibits osteoblast differentiation by targeting Runx2 to degradation  
 If S148 is required for Smurf1 inhibition of osteoblast differentiation because it targets Runx2 
for degradation, mutating S148 to alanine in Smurf1 should increase Runx2 accumulation and rescue 
in part, the CCD phenotype seen in Runx2+/- mice (Komori et al., 1997c; Otto et al., 1997a). To test 
this hypothesis, we analyzed Runx2+/-;Smurf1
ki/ki
 mice.  
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Alcian blue/alizarin red staining of skeletal preparations showed a marked improvement of 
the CCD phenotype in Runx2+/-;Smurf1
ki/ki
 compared to Runx2+/- mice (Figure 3A-C) while a western 
blot verified that Runx2 accumulation was increased in Runx2+/-;Smurf1
ki/ki 
skulls (Figure 3D). This 
increase in Runx2 accumulation resulted in an improved osteoblast differentiation as shown by the 
increased Ocn expression in E15.5 Runx2+/-;Smurf1
ki/ki
 compared to Runx2+/- embryos (Figure 3E). 
Ocn and Bsp expression was also significantly higher in bones of Runx2+/-;Smurf1
ki/ki
 compared to 
those of Runx2+/- mice at P10 when measured by qPCR (Figure 3F-G). 
Hence, the ability of Smurf1 to target Runx2 for degradation explains to a large extent why 
this E3 ubiquitin ligase inhibits osteoblast differentiation. That the rescue of the CCD phenotype was 
not complete in Runx2+/-;Smurf1
ki/ki
 mice is consistent with the notion that Smurf1 also acts through 
additional mechanisms to prevent osteoblast differentiation such as targeting MEKK2, Smad1 and 
Smad5 for degradation (Yamashita et al., 2005; Zhu et al., 1999). 
S148 is needed for Smurf1 ability to regulate glucose homeostasis  
To determine if S148 is necessary for the interaction of Smurf1 with its other substrates, we 
focused on the insulin receptor (InsR) because both Smurf1-/- mice and Smurf1
ki/ki
 mice were 
hypoglycemic and hyperinsulinemic (Figure 4A-C).  
Following its phosphorylation by AMPK, WT but not S148A Smurf1 interacts readily with the 
InsR (Figure 4D) and forced expression of WT but not S148A Smurf1 decreased the accumulation of 





 than in WT bones. That the accumulation of the InsR was not affected in other insulin target 
tissues, such as liver, white adipose tissue (WAT), and muscle in Smurf1-/- and Smurf1
ki/ki
 mice (Figure 
4F) is explained in part by the fact that Smurf1 expression is markedly higher in bone than in the liver, 
WAT and muscle (Figure 4G).  
Given these observations, we tested whether the hypoglycemia seen in Smurf1
ki/ki
 mice 
resulted in part, from an increase in insulin signaling in osteoblasts. Since insulin signaling in 
osteoblasts inhibits Osteoprotegerin (Opg) expression
 
(Ferron et al., 2010a), we used the expression 
of this gene in Smurf1
ki/ki
 femurs as a readout of insulin signaling in osteoblasts. In agreement with the 
increased accumulation of the InsR in bone (Figure 4F), Opg expression was decreased in Smurf1
ki/ki
 
compared to control femurs (Figure 4H) whereas Rankl expression was unchanged (Figure 4I). This 
decrease in Opg expression provides an explanation for the significant increase in the number of 
osteoclasts observed in the bones of adult Smurf1
ki/ki 
mice (Figure 4J). This increase in bone resorption 
parameters was not of sufficient amplitude to compensate for the increase in bone formation 
parameters. As a result, Smurf1
ki/ki 
mice had a high bone mass (Figure 2I-L).  
Since bone resorption is the mechanism whereby osteocalcin, a hormone that favors insulin 
secretion, is activated by decarboxylation (Ferron et al., 2010a), we measured the circulating levels of 
undercarboxyated and bioactive osteocalcin in control and Smurf1
ki/ki 
mice and observed that 
circulating undercarboxylated osteocalcin levels were approximately three-fold higher in Smurf1
ki/ki 
than in control mice (Figure 4K). Such an increase in circulating osteocalcin levels should lead to a 
133 
 
hyperinsulinemia and hypoglycemia as seen in Smurf1
ki/ki 
mice (Figure 4B-C). To demonstrate that this 





mice lacking one allele of Osteocalcin (Smurf1
ki/ki
;Ocn+/-). As shown in Figure 4L 
blood glucose levels were normal in Smurf1
ki/ki
;Ocn+/- mice. These results reveal the existence of a 


















The mechanisms regulating Runx2 accumulation in osteoblast progenitor cells have been a 
topic of intense investigation. This has led to the identification mostly on biochemical grounds, of 
several E3 ubiquitin ligases that would trigger Runx2 for degradation. Given the number of E3 ubiquitin 
ligases known to interact with Runx2, one could fear that disrupting the interaction of only one of them 
with Runx2 would not significantly hamper osteoblast differentiation in vivo. Instead, our investigation 
shows that deleting a single E3 ubiquitin ligase implicated in Runx2 degradation Smurf1, results in an 
increase in Runx2 accumulation leading to a premature osteoblast differentiation during embryonic 
development and increased bone formation post-natally. We further show that the majority of this 
function of Smurf1 requires a single amino acid, S148, be phosphorylated by AMPK (Wei, 2015). 
These results highlight the importance of Smurf1 and of this particular residue in this molecule in 
targeting Runx2 for degradation in vivo and regulating osteoblast differentiation. 
The functions of Smurf1 in osteoblasts extend beyond osteoblast differentiation and bone formation 
since by favoring the degradation of the InsR in osteoblasts, Smurf1 is a regulator of circulating 
osteocalcin levels. This explains the existence of hyperinsulinemia and hypoglycemia in Smurf1
ki/ki 
mice. Indeed, Smurf1 regulates bone resorption and the production of the active form of osteocalcin, a 
hormone that favors insulin secretion (Lee et al., 2007). As it is the case for its ability to regulate 
osteoblast differentiation, this function of Smurf1 requires the presence of S148. Altogether, our results 
provide a deeper understanding of the molecular regulation of Runx2 accumulation and of the 
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Figure 1. Regulation of osteoblast differentiation by Smurf1 in vivo 
A-B. Alcian blue/alizarin red staining of clavicles and skulls of P4 and P10 WT and Smurf1-/- mice, 
respectively.   
C. Opening of sagittal sutures in P10 Smurf1-/- and WT mice. 




E to F. qPCR analysis of Ocn (E) and Bsp (F) expression in femurs of E14.5 WT and Smurf1-/- 
embryos (n=5). 
G. In situ hybridization analysis of Ocn, Bsp and α1(I)Col expression in femurs of E14.5 Smurf1-/- and 
WT embryos. 
H. Runx2 accumulation in skulls of P10 WT and Smurf1-/- mice. 
I. Expression of Runx2 in the femurs of P10 WT and Smurf1-/- mice (n=6). N.S., not significant.  
Error bars indicate mean ± SEM. ∗p ≤ 0.05; 
#
p ≤ 0.005 (compared to control),when analyzed by 




Figure 2. Phosphorylation of Smurf1 at S148 is necessary for Smurf1 ability to regulate 
osteoblast differentiation in vivo  
A. Western blot analysis of S148 phosphorylation in Smurf1 in WT and Smurf1
ki/ki
 osteoblasts. 




A. Opening of sagittal sutures in P10 Smurf1
ki/ki
 and WT mice. 
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E-F. In situ hybridization analysis of Bsp in calvarial bones (E) and of Ocn, Bsp and α1(I)Col 
expression in femurs (F) of E14.5 WT and Smurf1
ki/ki 
embryos. 




I-L. Bone histomorphometric analysis of L3 and L4 vertebrae of 2 month-old WT and Smurf1
ki/ki
 female 
mice (n=7). Mineralized bone volume per total volume (BV/TV) (I). Trabecular number (Tb.N) (J). 
Osteoblast number per tissue area (N.Ob/T.Ar) (K). The annual fractional volume of trabecular bone 
formed per unit trabecular surface area (BFR/BS) (L).  
M. Runx2 accumulation in the skulls of P10 WT and Smurf1
ki/ki 
mice. 
N. GST-Pull down assay showing interaction of Flag-Runx2 with GST-Smurf1 WT or S148A after 
phosphorylation by AMPK.  
O. Effect of the forced expression of WT or S148A Smurf1 on the accumulation of Runx2 in COS-7 
cells. 
Error bars indicate mean ± SEM. ∗p ≤ 0.05; 
#
p ≤ 0.005 (compared to control), when analyzed by 




Figure 3. Smurf1 phosphorylation at S148 is necessary to regulate Runx2 in vivo 
A. Alcian blue/alizarin red staining of skulls of P10 Runx2+/- and Runx2+/-;Smurf1
ki/ki
 mice.  
B. Area of the opening of skulls in P10 Runx2+/-;Smurf1
ki/ki
 and Runx2 +/- mice. 
C. Alcian blue/alizarin red staining of clavicles of P10 Runx2+/- and Runx2+/-;Smurf1
ki/ki
 mice.  
D. Runx2 accumulation in skulls of P10 Runx2+/-, Runx2+/-;Smurf1
ki/ki
 and WT skulls.  






F-G. qPCR analysis of Ocn (F) and Bsp (G) expression in femurs of P10 WT, Runx2+/- and 
Runx2+/-;Smurf1
ki/ki
 mice (n=3-4). 
Error bars indicate mean ± SEM. ∗p ≤ 0.05; 
#
p ≤ 0.005 (compared to control),when analyzed by 




Figure 4. Phosphorylation of Smurf1 at S148 is necessary for Smurf1 activity to regulate InsR 
degradation  
A-B. Blood glucose levels in P10 WT and Smurf1-/- mice (A), WT and Smurf1
ki/ki
 mice (n=9-13 per 
group) (B). 
C. Circulating insulin levels in P10 WT and Smurf1
ki/ki
 mice (n=6). BDL: Below detection limit.  
D. GST-Pull down assay showing interaction of InsR with GST-Smurf1 WT or GST-Smurf1 S148A 
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after AMPK phosphorylation.  
E. Effect of the overexpression of WT or S148A Smurf1 on the accumulation of InsR in COS-7 cells. 
F. Accumulation of the InsR in skull, liver, WAT and muscle of P10 WT, Smurf1-/- and Smurf1
ki/ki
 mice.  
G. Expression of Smurf1 in liver, WAT, muscle and skull of P10 WT mice.  




J. Osteoclasts number (N.Oc/B.Pm (/mm)) in 2 month-old WT and Smurf1
ki/ki
 female mice (n=7).  
K. Serum levels of undercarboxylated osteocalcin in 2 month-old WT and Smurf1
ki/ki
 mice (n=6). 




 mice (n=9). 
Error bars indicate mean ± SEM. ∗p ≤ 0.05; 
#
p ≤ 0.005 (compared to control), when analyzed by 




Supplemental Figures  
 
Figure S1. Generation of Smurf1 S148A knock-in mice (related to Figure 3-2) 
A. Targeting strategy used to generate Smurf1 S148A knock-in allele.  
B. DNA sequencing analysis showing the Smurf1 S148A mutation.  





Figure S2. S148 in Smurf1 is necessary to inhibit osteoblast differentiation in vitro and in vivo   
(related to Figure2). 
A. Formation of mineralized nodules in WT, Smurf1-/- and Smurf1
ki/ki
 osteoblasts cultured for 7 days 
in differentiation medium followed by Von Kossa staining. 




Error bars indicate mean ± SEM. ∗p ≤ 0.05; 
#
p ≤ 0.005 (compared to control),when analyzed by 








General Conclusion: What is learned from my thesis 
In conclusion, work I performed during my thesis has revealed the fundamental importance of 
GLUT1-dependent glucose uptake in osteoblasts as an earliest determinant of osteoblast 
differentiation, bone formation and whole-body glucose homeostasis. Moreover, I have also shown that 
AMPK integrates glucose signals to favor, in two distinct but synergistic manners, osteoblast 
differentiation and bone formation. Indeed glucose uptake by preventing AMPK activation prevents 
Runx2 ubiquitination thereby favoring osteoblast differentiation to occur. At the same time glucose 
uptake in cells of the osteoblast lineage enhances protein synthesis thereby favoring bone formation. 
Furthermore, I have uncovered a feedforward regulation between Runx2 and Glut1 that acts as an 
amplification loop to initiate osteoblast differentiation during development and to regulate the extent of 
bone formation throughout life (Figure 1). Thus, these findings not only explain an apparent disconnect 
between the regulation of osteoblast differentiation and bone formation but also address in part the 
question of why bone acts as a regulator of whole-body glucose homeostasis by shedding light on the 
central importance of the intricate cross-talk between bone and glucose metabolism.  
Moreover, the physiological importance of crosstalk between glucose homeostasis and the 
skeletal development and functions is further supported by the identification of the necessity of AMPK 
phosphorylation at S148 in Smurf1 to fulfill its functions of the regulation of osteoblast differentiation, 
bone formation and the osteocalcin-regulated whole-body glucose homeostasis by targeting both 
Runx2 and the InsR for degradation in osteoblasts (Figure 2).  
Altogether, my thesis shows molecularly and genetically how the accumulation of a master 
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regulator of osteoblast differentiation, Runx2, is intimately linked to glucose homeostasis in osteoblasts 
and its physiological consequences that extend beyond osteoblast differentiation and bone formation 
to whole-body glucose homeostasis.  
 
Future Directions: What would be interesting to study next?  
Without doubts, there are several aspects described below that if further studied would 
strengthen the findings observed and expand the knowledge presented in this thesis.  
First, it would be interesting to further study how Glut1 expression is regulated before Runx2 
expression initiates in the early phase of osteoblast differentiation. This work has shown in vivo by in 
situ hybridization that the expression of Runx1, one of the members of the Runx family gene (Otto et 
al., 2003), is observed in cells expressing α1(I) Collagen and Glut1 in hind limb during development 
from E10.5 (Wei et al., 2015a). In vitro, luciferase assay showed that Runx1, in addition to Runx2, 
promotes activity of a Glut1 promoter as well (Wei et al., 2015a). Thus, further in vivo investigations of 
the initiation and regulation of the Glut1 expression and the potential crosstalk between Glut1 and 
Runx1 in the early phage of osteoblast differentiation would be interesting to better delineate the 
mechanism of osteoblast differentiation.  
Second, the identification of GLUT1-dependent glucose uptake as the determinant of 
osteoblast differentiation and functions leads to the question of whether there is/are an extracellular 
factor(s) that upregulates Glut1 expression in osteoblasts and thereby favoring the function of 
osteoblasts. Specifically, this question was raised by the clinical observations that osteoblastic 
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(bone-forming) metastasis to bone is observed in patients with prostate cancer in which Glut1 is 
robustly expressed (Carvalho et al., 2011; Logothetis and Lin, 2005). Thus, investigations of an 
extracellular factor(s) secreted by prostate cancer cells that promote Glut1 expression in osteoblasts, 
may be beneficial for better understanding of the pathological principle of bone metastasis associated 
with prostate cancer.  
Third, the extent of S148 phosphorylation-mediated regulation of Smurf1 activation would be 
interesting to study in vivo. Specifically,  questions that remain to be addressed are whether 
AMPK-phosphorylation site S148 in Smurf1 is needed for the ability of AMPK to target additional 
Smurf1 substrates besides Runx2 and the InsR for degradation and whether there is/are another 
kinase(s) besides AMPK that phosphorylates S148 and activates Smurf1. Furthermore, identification 
of phosphatase is critical to better understand the S148 phosphorylation-mediated regulation of 
Smurf1 activation. It is known that Smurf1 functions extend beyond its regulation of the osteoblast 
differentiation and bone mass reported in this thesis. Smurf1 is involved in a number of mechanisms 
including cell growth, polarity, adhesion as well as viral autophagy and immune responses by targeting 
a variety of substrates (Cao and Zhang, 2013). Since the knowledge of the mechanism of Smurf1 
activation is still limited, investigating the importance of Smurf1 phosphorylation at S148 may 
contribute to expand our understanding of the regulatory mechanism of Smurf1 activation.   
Furthermore, the important question remained to be addressed is how structurally the 
phosphorylation of S148 in Smurf1 results in the activation of Smurf1. This thesis reports that S148 
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phosphorylation by AMPK enhances the interaction between Smurf1 and its substrates, Runx2 and the 
InsR in vitro. However, the biochemical evidence of the possible changes in the structural confirmation 
that leads to the enhancement of the affinity of Smurf1 to the substrates upon S148 phosphorylation by 
AMPK is missing. Thus, delineating structurally the mode of the AMPK-mediated activation of Smurf1 
will also contribute to expand our knowledge about the regulation of the activation of Smurf1, this may 
also be beneficial of Smurf1 becomes as a therapeutic target for diseases such as osteoporosis and 
CCD.  
Lastly, the identification of a novel function of AMPK to regulate protein accumulation by 
phosphorylating E3 ubiquitin ligase raises the question of whether AMPK targets other E3 ligases in 
vivo. Even in the context of bone biology, Smurf1 is not the only E3 ubiquitin ligase that regulates 
osteoblast biology. Thus, further investigations to search for the AMPK targets among E3 ubiquitin 
ligases are warranted as they may expand our knowledge on how cells integrate energy homeostasis 





Figure 1. Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and 
bone formation 
Schematic view of the regulation of osteoblast differentiation and bone formation by crosstalk between 






Figure 2. A single amino acid explains how Smurf1 regulate osteoblast differentiation, bone 
formation and glucose homeostasis 
Schematic view of Smurf1 regulation of osteoblast differentiation, bone formation and glucose 
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